Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 05, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | LIVE OAK BANCSHARES, INC. | |
Entity Central Index Key | 0001462120 | |
Trading Symbol | LOB | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Entity Current Reporting Status | Yes | |
Entity Shell Company | false | |
Entity File Number | 001-37497 | |
Entity Tax Identification Number | 26-4596286 | |
Entity Address, Address Line One | 1741 Tiburon Drive | |
Entity Address, City or Town | Wilmington | |
Entity Address, State or Province | NC | |
Entity Address, Postal Zip Code | 28403 | |
City Area Code | 910 | |
Local Phone Number | 790-5867 | |
Entity Interactive Data Current | Yes | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Title of 12(b) Security | Voting Common Stock, no par value per share | |
Security Exchange Name | NASDAQ | |
Entity Incorporation, State or Country Code | NC | |
Entity Voting Common Stock | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding (in shares) | 37,793,904 | |
Entity Nonvoting Common Stock | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding (in shares) | 2,715,531 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Assets | ||
Cash and due from banks | $ 256,824 | $ 126,752 |
Federal funds sold | 158,226 | 96,787 |
Certificates of deposit with other banks | 7,250 | 7,250 |
Investment securities available-for-sale | 574,168 | 540,045 |
Loans held for sale (includes $19,151 and $16,198 measured at fair value, respectively) | 996,050 | 966,447 |
Loans and leases held for investment (includes $831,426 and $824,520 measured at fair value, respectively) | 2,817,491 | 2,627,286 |
Allowance for credit losses on loans and leases | (35,906) | (28,234) |
Net loans and leases | 2,781,585 | 2,599,052 |
Premises and equipment, net | 274,177 | 279,099 |
Foreclosed assets | 6,744 | 5,612 |
Servicing assets | 33,532 | 35,365 |
Operating lease right-of-use assets | 2,236 | 2,427 |
Other assets | 185,524 | 156,134 |
Total assets | 5,276,316 | 4,814,970 |
Deposits: | ||
Noninterest-bearing | 54,022 | 54,107 |
Interest-bearing | 4,588,126 | 4,175,015 |
Total deposits | 4,642,148 | 4,229,122 |
Borrowings | 50,012 | 14 |
Operating lease liabilities | 2,416 | 2,619 |
Other liabilities | 47,968 | 50,829 |
Total liabilities | 4,742,544 | 4,282,584 |
Shareholders’ equity | ||
Retained earnings | 172,276 | 180,265 |
Accumulated other comprehensive income | 17,749 | 11,724 |
Total shareholders’ equity | 533,772 | 532,386 |
Total liabilities and shareholders’ equity | 5,276,316 | 4,814,970 |
Preferred Stock Undefined | ||
Shareholders’ equity | ||
Preferred stock, no par value, 1,000,000 authorized, none issued or outstanding at March 31, 2020 and December 31, 2019 | ||
Class A Common Stock | ||
Shareholders’ equity | ||
Common stock | 314,994 | 309,526 |
Class B Common Stock | ||
Shareholders’ equity | ||
Common stock | $ 28,753 | $ 30,871 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Loans held-for-sale, fair value | $ 19,151 | $ 16,198 |
Loans and leases held for Investment at fair value | $ 831,426 | $ 824,520 |
Preferred Stock Undefined | ||
Preferred stock, par value | ||
Preferred stock authorized (in shares) | 1,000,000 | 1,000,000 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Class A Common Stock | ||
Common stock, par value | ||
Common stock authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock issued (in shares) | 37,664,670 | 37,401,443 |
Common stock outstanding (in shares) | 37,664,670 | 37,401,443 |
Class B Common Stock | ||
Common stock, par value | ||
Common stock authorized (in shares) | 10,000,000 | 10,000,000 |
Common stock issued (in shares) | 2,715,531 | 2,915,531 |
Common stock outstanding (in shares) | 2,715,531 | 2,915,531 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Interest income | ||
Loans and fees on loans | $ 58,961 | $ 44,966 |
Investment securities, taxable | 3,762 | 3,317 |
Other interest earning assets | 750 | 1,639 |
Total interest income | 63,473 | 49,922 |
Interest expense | ||
Deposits | 23,255 | 19,317 |
Borrowings | 57 | |
Total interest expense | 23,312 | 19,317 |
Net interest income | 40,161 | 30,605 |
Provision for loan and lease credit losses | 11,792 | 3,031 |
Net interest income after provision for loan and lease credit losses | 28,369 | 27,574 |
Noninterest income | ||
Loan servicing revenue | 6,422 | 7,410 |
Loan servicing asset revaluation | (4,692) | (4,040) |
Net gains on sales of loans | 11,112 | 4,198 |
Net (loss) gain on loans accounted for under the fair value option | (10,638) | 2,083 |
Equity method investments income (loss) | (2,478) | (2,014) |
Equity security investments (losses) gains, net | (64) | 103 |
(Loss) gain on sale of investment securities available-for-sale | (79) | 5 |
Lease income | 2,624 | 2,325 |
Management fee income | 1,644 | |
Construction supervision fee income | 390 | 779 |
Other noninterest income | 1,501 | 2,467 |
Total noninterest income | 5,742 | 13,316 |
Noninterest expense | ||
Salaries and employee benefits | 28,063 | 21,855 |
Travel expense | 1,781 | 1,200 |
Professional services expense | 1,937 | 2,182 |
Advertising and marketing expense | 1,361 | 1,364 |
Occupancy expense | 2,421 | 1,609 |
Data processing expense | 3,157 | 2,399 |
Equipment expense | 4,635 | 3,325 |
Other loan origination and maintenance expense | 2,456 | 1,639 |
FDIC insurance | 1,510 | 635 |
Other expense | 2,170 | 1,993 |
Total noninterest expense | 49,491 | 38,201 |
(Loss) income before taxes | (15,380) | 2,689 |
Income tax (benefit) expense | (7,778) | 317 |
Net (loss) income | $ (7,602) | $ 2,372 |
Basic (loss) earnings per share | $ (0.19) | $ 0.06 |
Diluted (loss) earnings per share | $ (0.19) | $ 0.06 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Statement Of Income And Comprehensive Income [Abstract] | ||
Net (loss) income | $ (7,602) | $ 2,372 |
Other comprehensive income before tax: | ||
Net unrealized gain on investment securities arising during the period | 7,849 | 3,518 |
Reclassification adjustment for loss (gain) on sale of securities available-for-sale included in net income | 79 | (5) |
Other comprehensive income before tax | 7,928 | 3,513 |
Income tax expense | (1,903) | (843) |
Other comprehensive income, net of tax | 6,025 | 2,670 |
Total comprehensive (loss) income | $ (1,577) | $ 5,042 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands | Total | Common stock | Common stockClass A Common Stock | Common stockClass B Common Stock | Retained earnings | Accumulated other comprehensive income (loss) |
Beginning balance at Dec. 31, 2018 | $ 493,560 | $ 328,113 | $ 167,124 | $ (1,677) | ||
Beginning balance (in shares) at Dec. 31, 2018 | 35,512,262 | 4,643,530 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net (loss) income | 2,372 | 2,372 | ||||
Other comprehensive income | 2,670 | 2,670 | ||||
Issuance of restricted stock | 0 | |||||
Issuance of restricted stock (in shares) | 2,140 | |||||
Withholding cash issued in lieu of restricted stock issuance | (5) | (5) | ||||
Employee stock purchase program | 182 | 182 | ||||
Employee stock purchase program (in shares) | 14,059 | |||||
Stock option exercises | 14 | 14 | ||||
Stock option exercises (in shares) | 3,088 | |||||
Stock option based compensation expense | 470 | 470 | ||||
Restricted stock expense | 2,388 | 2,388 | ||||
Cash dividends | (1,205) | (1,205) | ||||
Ending balance at Mar. 31, 2019 | 500,380 | 331,162 | 168,225 | 993 | ||
Ending balance (in shares) at Mar. 31, 2019 | 35,531,549 | 4,643,530 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Cumulative effect of accounting change for Accounting Standards Update | Accounting Standards Update 2016-02 | (66) | (66) | ||||
Beginning balance at Dec. 31, 2019 | 532,386 | 340,397 | 180,265 | 11,724 | ||
Beginning balance (in shares) at Dec. 31, 2019 | 37,401,443 | 2,915,531 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net (loss) income | (7,602) | (7,602) | ||||
Other comprehensive income | 6,025 | 6,025 | ||||
Issuance of restricted stock | 0 | |||||
Issuance of restricted stock (in shares) | 7,424 | |||||
Withholding cash issued in lieu of restricted stock issuance | (48) | (48) | ||||
Employee stock purchase program | 232 | 232 | ||||
Employee stock purchase program (in shares) | 25,161 | |||||
Stock option exercises | 258 | 258 | ||||
Stock option exercises (in shares) | 30,642 | |||||
Stock option based compensation expense | 366 | 366 | ||||
Restricted stock expense | 2,542 | 2,542 | ||||
Non-voting common stock converted to voting common stock in private sale (in shares) | 200,000 | (200,000) | ||||
Cash dividends | (1,209) | (1,209) | ||||
Ending balance at Mar. 31, 2020 | 533,772 | $ 343,747 | 172,276 | $ 17,749 | ||
Ending balance (in shares) at Mar. 31, 2020 | 37,664,670 | 2,715,531 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Cumulative effect of accounting change for Accounting Standards Update | Accounting Standards Update 2016-13 | $ 822 | $ 822 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Statement Of Stockholders Equity [Abstract] | ||
Cash dividends per share | $ 0.03 | $ 0.03 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities | ||
Net (loss) income | $ (7,602) | $ 2,372 |
Adjustments to reconcile net (loss) income to net cash used by operating activities: | ||
Depreciation and amortization | 5,621 | 4,034 |
Provision for loan and lease credit losses | 11,792 | 3,031 |
Amortization of premium on securities, net of accretion | 269 | 105 |
Deferred tax expense (benefit) | 1,264 | (632) |
Originations of loans held for sale | (274,678) | (206,440) |
Proceeds from sales of loans held for sale | 203,340 | 80,931 |
Net gains on sale of loans held for sale | (11,112) | (4,198) |
Net loss on sale of foreclosed assets | 49 | |
Net loss (gain) on loans accounted for under fair value option | 10,638 | (2,083) |
Net decrease in servicing assets | 1,833 | 3,317 |
Loss (gain) on sale of securities available-for-sale | 79 | (5) |
Net gain on disposal of long-lived asset | (357) | |
Net loss on disposal of property and equipment | 38 | |
Equity method investments (income) loss | 2,478 | 2,014 |
Equity security investments losses (gains), net | 64 | (103) |
Stock option based compensation expense | 366 | 470 |
Restricted stock expense | 2,542 | 2,388 |
Stock based compensation expense tax shortfall | (34) | (8) |
Changes in assets and liabilities: | ||
Lease right-of-use assets and liabilities, net | (12) | 114 |
Other assets | (31,962) | 7,867 |
Other liabilities | (6,493) | (605) |
Net cash used by operating activities | (91,520) | (107,788) |
Cash flows from investing activities | ||
Purchases of securities available-for-sale | (52,757) | (198,384) |
Proceeds from sales, maturities, calls, and principal paydown of securities available-for-sale | 26,214 | 12,548 |
Proceeds from SBA reimbursement/sale of foreclosed assets | 613 | 393 |
Loan and lease originations and principal collections, net | (152,559) | (113,064) |
Proceeds from sale of long-lived asset | 10,895 | |
Purchases of premises and equipment, net | (737) | (13,315) |
Net cash used by investing activities | (179,226) | (300,927) |
Cash flows from financing activities | ||
Net increase in deposits | 413,026 | 378,822 |
Proceeds from borrowings | 50,000 | |
Repayment of borrowings | (2) | (49) |
Stock option exercises | 258 | 14 |
Employee stock purchase program | 232 | 182 |
Withholding cash issued in lieu of restricted stock | (48) | (5) |
Shareholder dividend distributions | (1,209) | (1,205) |
Net cash provided by financing activities | 462,257 | 377,759 |
Net increase (decrease) in cash and cash equivalents | 191,511 | (30,956) |
Cash and cash equivalents, beginning | 223,539 | 316,823 |
Cash and cash equivalents, ending | 415,050 | 285,867 |
Supplemental disclosures of cash flow information | ||
Interest paid | 23,858 | 17,837 |
Income tax paid (received) | 362 | (13,654) |
Supplemental disclosures of noncash operating, investing, and financing activities | ||
Unrealized holding gains on available-for-sale securities, net of taxes | 6,025 | 2,670 |
Transfers from loans and leases to foreclosed real estate and other repossessions | 1,764 | 707 |
Net transfers between foreclosed real estate and SBA receivable | 30 | |
Right-of-use assets obtained in exchange for lessee operating lease liabilities | 2,241 | |
Transfer of loans held for sale to loans and leases held for investment | 35,233 | 50,055 |
Transfer of loans and leases held for investment to loans held for sale | $ 2,949 | $ 8,845 |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Basis of Presentation | Live Oak Bancshares, Inc. Notes to Unaudited Condensed Consolidated Financial Statements Note 1. Basis of Presentation Nature of Operations Live Oak Bancshares, Inc. (the “Company” or “LOB”) is a bank holding company headquartered in Wilmington, North Carolina incorporated under the laws of North Carolina in December 2008. The Company conducts business operations primarily through its commercial bank subsidiary, Live Oak Banking Company (the “Bank”). The Bank was organized and incorporated under the laws of the State of North Carolina on February 25, 2008 and commenced operations on May 12, 2008. The Bank specializes in providing lending services to small businesses nationwide. The Bank identifies and grows lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A significant portion of the loans originated by the Bank are guaranteed by the Small Business Administration (“SBA”) under the 7(a) Loan Program and the U.S. Department of Agriculture ("USDA") Rural Energy for America Program ("REAP"), Water and Environmental Program (“WEP”) and The Bank’s wholly owned subsidiaries are Live Oak Number One, Inc., Live Oak Clean Energy Financing LLC (“LOCEF”), and Live Oak Private Wealth, LLC. The Company’s wholly owned subsidiaries are the Bank, Government Loan Solutions (“GLS”), Live Oak Grove, LLC (“the Grove”), Live Oak Ventures, Inc. (“Live Oak Ventures”), and Canapi Advisors, LLC (“Canapi”). Live Oak Number One, Inc. holds properties foreclosed on by the Bank. GLS is a management and technology consulting firm that advises and offers solutions and services to participants in the government guaranteed lending sector. GLS primarily provides services in connection with the settlement, accounting, and securitization processes for government guaranteed loans, including loans originated under the SBA 7(a) loan programs and USDA guaranteed loans. The Grove provides Company employees and business visitors an on-site restaurant location. Live Oak Ventures’ purpose is investing in businesses that align with the Company's strategic initiative to be a leader in financial technology. LOCEF provides financing to entities for renewable energy applications and became a wholly owned subsidiary of the Bank during the first quarter of 2019. Live Oak Private Wealth, LLC provides high-net-worth individuals and families with strategic wealth and investment management services. Canapi provides investment advisory services to a series of new funds focused on providing venture capital to new and emerging financial technology companies. The Company jointly formed 504 Fund Advisors, LLC (“504FA”) to serve as the investment adviser for the 504 Fund, a closed-end mutual fund organized to invest in SBA section 504 loans. 504FA exited as advisor for the 504 Fund in May 2019 and the Company subsequently dissolved this legal entity. The Company generates revenue primarily from net interest income and secondarily through the origination and sale of government guaranteed loans. Income from the retention of loans is comprised of interest income. The Company elects to account for certain loans under the fair value option with interest reported in interest income and changes in fair value reported in the net (loss) gain on loans accounted for under the fair value option line item of the consolidated statements of income. Income from the sale of loans is comprised of loan servicing revenue and revaluation of related servicing assets along with net gains on sales of loans. Offsetting these revenues are the cost of funding sources, provision for loan and lease credit losses, any costs related to foreclosed assets and other operating costs such as salaries and employee benefits, travel, professional services, advertising and marketing and tax expense. General In the opinion of management, all adjustments necessary for a fair presentation of the financial position and results of operations for the periods presented have been included, and all intercompany transactions have been eliminated in consolidation. Results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2020. The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities Exchange Commission on February 27, 2020 (SEC File No. 001-37497) (the "2019 Annual Report"). A summary description of the significant accounting policies followed by the Company is set forth in Note 1 of the Notes to Consolidated Financial Statements in the Company’s 2019 Annual Report. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes in the Company's 2019 Annual Report. The preparation of financial statements in conformity with United States generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. Amounts in all tables in the Notes to Unaudited Condensed Consolidated Financial Statements have been presented in thousands, except percentage, time period, stock option, share and per share data or where otherwise indicated. Business Segments Management has determined that the Company has one significant operating segment, which is providing a lending platform for small businesses nationwide. In determining the appropriateness of segment definition, the Company considers the materiality of a potential segment, the components of the business about which financial information is available, and components for which management regularly evaluates relative to resource allocation and performance assessment. Reclassifications Certain reclassifications have been made to the prior period’s consolidated financial statements to place them on a comparable basis with the current year. Net income and shareholders’ equity previously reported were not affected by these reclassifications. Current period reclassifications were primarily related to fair value presentation requirements for loans in which the fair value option had previously been elected and included a reclassification of amounts representing the credit component of the fair value discount that was previously reported as a component of the allowance for credit losses on loans and leases to be netted directly against loans and leases held for investment on the Company’s consolidated balance sheet. Amounts reclassified from the allowance for credit losses on loans and leases to net directly against total loans and leases held for investment was $20.0 million, as of December 31, 2019. In addition, the change in the credit component of the fair value discount was previously reported in the provision for loan and lease credit losses while the change in the liquidity component of the fair value discount was previously reported in the loan servicing asset revaluation in the consolidated statements of income, but both have now been reclassified to net (loss) gain on loans accounted for under the fair value option. Amounts reclassified from the provision for loan and lease credit losses and the loan servicing asset revaluation to net (loss) gain on loans accounted for under the fair value option were $(289) thousand and $(1.8) million, respectively, for the quarter ended March 31, 2019. The effect of the above discussed reclassifications on the consolidated balance sheets, consolidated statements of income, and consolidated statements of cash flows for each period are presented below, with additional parenthetical disclosures added: As Reported Reclassifications As Reclassified Consolidated Balance Sheet as of December 31, 2019 Loans held for sale $ 966,447 $ — $ 966,447 Loans and leases held for investment 2,647,299 (20,013 ) 2,627,286 Allowance for credit losses on loans and leases (48,247 ) 20,013 (28,234 ) Net loans and leases 2,599,052 — 2,599,052 Total assets 4,814,970 — 4,814,970 Consolidated Statement of Income for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net interest income after provision for loan and lease credit losses 27,863 (289 ) 27,574 Loan servicing asset revaluation (2,246 ) (1,794 ) (4,040 ) Net (loss) gain on loans accounted for under the fair value option — 2,083 2,083 Total noninterest income 13,027 289 13,316 Net income 2,372 — 2,372 Consolidated Statement of Cash Flows for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net decrease in servicing assets 3,317 — 3,317 Change in discount on unguaranteed loans (1,319 ) 1,319 — Net loss (gain) on loans accounted for under fair value option — (2,083 ) (2,083 ) Net cash used by operating activities (107,313 ) (475 ) (107,788 ) Loan and lease originations and principal collections, net (113,539 ) 475 (113,064 ) Net cash used by investing activities (301,402 ) 475 (300,927 ) Adoption of New Accounting Standard On January 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”) along with its amendments, which replaces the incurred loss impairment methodology in current standards with the current expected credit loss methodology (“CECL”) and requires consideration of a broader range of information to determine credit loss estimates. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts and requires enhanced disclosures related to the significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell. The Company adopted Accounting Standards Codification (“ASC”) 326 using the modified retrospective method for all financial assets measured at amortized cost and off-balance-sheet credit exposures. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 while prior period amounts continue to be reported in accordance with previously applicable GAAP. The Company recorded a net increase to retained earnings of $822 thousand, comprised of a $1.3 million decrease in the allowance for credit losses combined with a $499 thousand increase in reserve on unfunded commitments, as of January 1, 2020 for the cumulative effect of adopting ASC 326. Allowance for Credit Losses – Loans and Leases Held for Investment The allowance for credit losses (“ACL”) is a valuation account that is deducted from, or added to, the amortized cost basis of loans and leases to present a net amount expected to be collected. The ACL excludes loans held for sale and loans accounted for under the fair value option. Loans and leases are charged-off against the ACL when management believes the uncollectibility of a loan or lease balance is confirmed. Expected recoveries do not exceed the aggregate of amounts previously charged-off and expected to be charged-off. The Company’s ACL on loans and leases is estimated using relevant information, from internal and external sources, relating to past events, current conditions, and reasonable and supportable forecasts. The Company’s historical credit loss experience provides the basis for the estimation of expected credit losses. Management adjusts historical loss information for differences in current risk characteristics such as portfolio risk grading, delinquency levels, or portfolio mix as well as for changes in environmental conditions such as changes in unemployment rates. The ACL is measured on a pooled basis when similar risk characteristics are present in the portfolio. The Company has identified portfolio segments based on industry and whether the receivable is secured by real estate or another form of collateral. Additional information related to the portfolio segments can be found in the Company’s 2019 Form 10-K. Expected credit losses for pooled loans and leases are estimated using a discounted cash flow (“DCF”) methodology. Loans or leases that do not share risk characteristics are evaluated on an individual basis and are excluded from the pooled evaluation. This generally occurs when, based on current information and events, it is probable that the Company will be unable to collect all interest and principal payments due according to the originally contracted, or reasonably modified, terms of the loan or lease agreement. The Company has determined that loans and leases meeting the criteria defined below must be reviewed quarterly to determine if they should be evaluated for expected credit losses on an individual basis. • All commercial loans and leases classified substandard or worse. • Any loan or lease that is on nonaccrual, or any loan or lease that is delinquent greater than 90 days past due and still accruing interest. • Any loan or lease that it meets the definition of a troubled debt restructuring (“TDR”). Expected credit losses are estimated over the contractual term of the loan or lease, adjusted for expected prepayments when appropriate. The contractual term excludes expected extensions, renewals, and modifications unless management has a reasonable expectation at the reporting date that a TDR will be executed with an individual borrower or the extension or renewal options are included in the contract at the reporting date and are not unconditionally cancellable by the Company. When the ACL, for pooled or individually evaluated loans and leases, is estimated using the DCF method, the effective interest rate used to discount expected cash flows is adjusted for expected prepayments. Past due status of loans and leases is determined based on contractual terms. Loans and leases are placed in nonaccrual status and interest accrual is discontinued if they become 90 days delinquent or there is evidence that the borrower’s ability to make the required payments is impaired. A loan or lease is accounted for as a TDR if the Company, for reasons related to the borrower’s financial difficulties, restructures a loan or lease, and grants a concession to the borrower that it would not otherwise grant. A TDR typically involves a more than short-term modification of terms such as a reduction of the interest rate below the current market rate for a loan or lease with similar risk characteristics or the waiving of certain financial covenants without corresponding offsetting compensation or additional support. When management determines that foreclosure is probable or when the borrower is experiencing financial difficulty at the reporting date and repayment is expected to be provided substantially through the operation or sale of the collateral, expected credit losses are based on the fair value of the collateral at the reporting date, adjusted for selling costs as appropriate. Allowance for Credit Losses – Off-Balance Sheet Credit Exposures Expected credit losses on off-balance sheet credit exposures is estimated over the contractual period in which the Company is exposed to such losses, unless the obligation to extend credit is unconditionally cancellable. The estimate of off-balance sheet credit exposures includes consideration of the likelihood that funding will occur and an estimate of expected credit losses on commitments expected to be funded over its estimated losses. The estimate is influenced by historical loss experience, adjusted for current risk characteristics, and economic forecasts. Allowance for Credit Losses – Available-for-Sale Securities When available-for-sale debt securities are in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. Available-for-sale debt securities that do not meet the aforementioned criteria are evaluated to determine whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected from the security is less than the amortized cost basis, a credit loss exists and an ACL is recorded for the credit loss, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. Changes in the ACL are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. Management has made the accounting policy election to exclude accrued interest receivable on available-for-sale debt securities from the estimate of credit losses. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through income when deemed uncollectible by management or when either of the aforementioned criteria regarding intent or requirement to sell is met. Common Stock On March 15, 2020, the Board of Directors of the Company authorized the repurchase of up to $20,000,000 in shares of the Company’s voting common stock from time to time through December 31, 2020 (the “Repurchase Program”). The Repurchase Program enables the Company to acquire shares through open market purchases or privately negotiated transactions, including through a Rule 10b5-1 plan, at the discretion of management and on terms (including quantity, timing, and price) that management determines to be advisable. Actions in connection with the repurchase program will be subject to various factors, including the Company’s capital and liquidity positions, regulatory and accounting considerations, the Company’s financial and operational performance, alternative uses of capital, the trading price of the Company’s common stock, and market conditions. The repurchase program does not obligate the Company to acquire a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time. There were no shares repurchased during the three months ended March 31, 2020 |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Recent Accounting Pronouncements | Note 2. Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain fair value disclosure requirements on fair value measurements. The Company adopted the standard on January 1, 2020 with no material effect on its consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted the standard on January 1, 2020 with no material effect on its consolidated financial statements. In March 2019, the FASB issued ASU No. 2019-01, “Leases (Topic 842): Codification Improvements” (“ASU 2019-01”). ASU 2019-01 provides updates to Topic 842 including: (i) guidance on how to determine fair value of leased items for lessors who are not dealers or manufacturers, (ii) cash flow presentation for lessors of sales-type and direct financing leases and (iii) clarifies certain transition disclosures. The Company adopted the standard on January 1, 2020 with no material effect on its consolidated financial statements . In April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” (“ASU 2019-04”). ASU 2019-04 provides clarification and minor improvements related to ASU 2016-01 “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and ASU 2017-12 “Derivatives and Hedging (Topic 815) - Targeted Improvements to Accounting for Hedging Activities.” The Company adopted the standard on January 1, 2020 with no material effect on its consolidated financial statements. In January 2020, the FASB issued ASU No. 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815” (“ASU 2020-01”). ASU 2020-01 clarifies the interaction between accounting standards related to equity securities, equity method investments, and certain derivatives including accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. The amendments in this standard will be effective for the Company on January 1, 2021. The Company does not expect this standard to have a material effect on its consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). The amendments represent clarification and improvements to the codification and correct unintended application. This standard was effective immediately upon issuance and its adoption did not have a material effect on the Company’s consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments are effective for the Company as of March 12, 2020 through December 31, 2022. The Company does not believe this standard will have a material impact on its consolidated financial statements. |
Earnings Per Share
Earnings Per Share | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Note 3. Earnings Per Share Basic and diluted earnings per share are computed based on the weighted average number of shares outstanding during each period. Diluted earnings per share reflects the potential dilution that could occur, upon the exercise of stock options or upon the vesting of restricted stock grants, any of which would result in the issuance of common stock that would then be shared in the net income of the Company. Three Months Ended March 31, 2020 2019 Basic (loss) earnings per share: Net (loss attributable to) income available to common shareholders $ (7,602 ) $ 2,372 Weighted-average basic shares outstanding 40,334,179 40,160,118 Basic (loss) earnings per share $ (0.19 ) $ 0.06 Diluted (loss) earnings per share: Net (loss attributable to) income available to common shareholders, for diluted (loss) earnings per share $ (7,602 ) $ 2,372 Total weighted-average basic shares outstanding 40,334,179 40,160,118 Add effect of dilutive stock options and restricted stock grants 739,870 761,705 Total weighted-average diluted shares outstanding 41,074,049 40,921,823 Diluted (loss) earnings per share $ (0.19 ) $ 0.06 Anti-dilutive shares 1,839,601 1,597,589 |
Investment Securities
Investment Securities | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Investment Securities | Note 4. Investment Securities The carrying amount of investment securities and their approximate fair values are reflected in the following table: March 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Allowance for Credit Losses Fair Value US treasury securities $ 4,992 $ 51 $ — $ — $ 5,043 US government agencies 22,444 635 — — 23,079 Mortgage-backed securities 514,899 22,950 558 — 537,291 Municipal bonds 8,479 283 7 — 8,755 Total $ 550,814 $ 23,919 $ 565 $ — $ 574,168 December 31, 2019 US treasury securities $ 4,988 $ 27 $ — $ — $ 5,015 US government agencies 22,444 335 — — 22,779 Mortgage-backed securities 488,694 15,530 927 — 503,297 Municipal bonds 8,493 469 8 — 8,954 Total $ 524,619 $ 16,361 $ 935 $ — $ 540,045 During the three months ended March 31, 2020, two mortgage-backed securities totaling $4.5 million were sold resulting in a net loss of $79 thousand. During the three months ended March 31, 2019, $900 thousand of one municipal bond was sold resulting in a net gain of $5 thousand. Accrued interest receivable on available-for-sale securities totaled $ 1.8 1.6 The following tables show debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position. Less Than 12 Months 12 Months or More Total March 31, 2020 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Mortgage-backed securities $ 36,320 $ 213 $ 25,032 $ 345 $ 61,352 $ 558 Municipal bonds — — 93 7 93 7 Total $ 36,320 $ 213 $ 25,125 $ 352 $ 61,445 $ 565 Less Than 12 Months 12 Months or More Total December 31, 2019 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Mortgage-backed securities $ 42,835 $ 460 $ 36,518 $ 467 $ 79,353 $ 927 Municipal bonds — — 92 8 92 8 Total $ 42,835 $ 460 $ 36,610 $ 475 $ 79,445 $ 935 Management evaluates available-for-sale debt securities to determine whether the unrealized loss is due to credit related factors or non-credit related factors. The evaluation considers the extent to which the security’s fair value is less than cost, the financial condition and near-term prospects of the issuer, and intent and ability of the Company to retain its investment in the security for a period of time sufficient to allow for any anticipated recovery in fair value. At March 31, 2020, there were fifteen mortgage-backed securities and one municipal bond in unrealized loss positions for greater than 12 months and twelve mortgage-backed securities in unrealized loss positions for less than 12 months. Unrealized losses at December 31, 2019 were comprised of twenty-two These unrealized losses are primarily the result of non-credit related volatility in the market and market interest rates. Since none of the unrealized losses relate to marketability of the securities or the issuer’s ability to honor redemption obligations and the Company has the intent and ability to hold the securities for a sufficient period of time to recover unrealized losses, none of the losses have been recognized in the Company’s consolidated statements of income. All mortgage-backed securities in the Company’s portfolio at March 31, 2020 and December 31, 2019 were backed by U.S. government sponsored enterprises (“GSEs”). The following is a summary of investment securities by maturity: March 31, 2020 Amortized cost Fair value US treasury securities Within one year $ 4,992 $ 5,043 Total 4,992 5,043 US government agencies Within one year 7,007 7,070 One to five years 12,518 12,901 Five to ten years 2,919 3,108 Total 22,444 23,079 Mortgage-backed securities One to five years 4,700 4,853 Five to ten years 178,652 191,718 After 10 years 331,547 340,720 Total 514,899 537,291 Municipal bonds After 10 years 8,479 8,755 Total 8,479 8,755 Total $ 550,814 $ 574,168 The table above reflects contractual maturities. Actual results will differ as the loans underlying the mortgage-backed securities may repay sooner than scheduled. There were no securities pledged at March 31, 2020 or December 31, 2019. |
Loans and Leases Held for Inves
Loans and Leases Held for Investment and Credit Quality | 3 Months Ended |
Mar. 31, 2020 | |
Receivables [Abstract] | |
Loans and Leases Held for Investment and Credit Quality | Note 5. Loans and Leases Held for Investment and Credit Quality The following tables present total loans and leases and an aging analysis for the Company’s portfolio segments. Loans and leases are considered past due if the required principal and interest payments have not been received as of the date such payments were due. Current or Less than 30 Days Past Due 30-89 Days Past Due 90 Days or More Past Due Total Past Due Total Carried at Amortized Cost 1 Loans Accounted for Under the Fair Value Option 2 Total Loans and Leases March 31, 2020 Commercial & Industrial Agriculture $ 10,370 $ 1 $ — $ 1 $ 10,371 $ 361 $ 10,732 Funeral Home & Cemetery 15,092 — — — 15,092 12,036 27,128 Healthcare 26,877 1,719 1,322 3,041 29,918 19,826 49,744 Independent Pharmacies 25,320 — — — 25,320 78,540 103,860 Registered Investment Advisors 40,269 — — — 40,269 58,016 98,285 Veterinary Industry 31,336 481 — 481 31,817 20,643 52,460 Other Industries 442,930 10,271 5,637 15,908 458,838 172,072 630,910 Total 592,194 12,472 6,959 19,431 611,625 361,494 973,119 Construction & Development Agriculture 45,333 — — — 45,333 — 45,333 Funeral Home & Cemetery 9,146 — — — 9,146 — 9,146 Healthcare 97,404 3,387 — 3,387 100,791 — 100,791 Independent Pharmacies 720 — — — 720 — 720 Registered Investment Advisors 2,564 — — — 2,564 — 2,564 Veterinary Industry 20,862 — — — 20,862 — 20,862 Other Industries 193,181 — — — 193,181 — 193,181 Total 369,210 3,387 — 3,387 372,597 — 372,597 Commercial Real Estate Agriculture 1,291 — — — 1,291 762 2,053 Funeral Home & Cemetery 58,699 — — — 58,699 58,611 117,310 Healthcare 140,375 — 4,498 4,498 144,873 107,437 252,310 Independent Pharmacies 8,609 — 822 822 9,431 17,182 26,613 Registered Investment Advisors 2,635 — — — 2,635 4,591 7,226 Veterinary Industry 68,831 2,953 1,089 4,042 72,873 71,129 144,002 Other Industries 427,669 6,326 1,849 8,175 435,844 92,105 527,949 Total 708,109 9,279 8,258 17,537 725,646 351,817 1,077,463 Commercial Land Agriculture 268,096 — 2,170 2,170 270,266 118,115 388,381 Total 268,096 — 2,170 2,170 270,266 118,115 388,381 Total $ 1,937,609 $ 25,138 $ 17,387 $ 42,525 $ 1,980,134 $ 831,426 $ 2,811,560 Net Deferred Costs $ 5,931 Loan and Leases, Net of unearned $ 2,817,491 Current or Less than 30 Days Past Due 30-89 Days Past Due 90 Days or More Past Due Total Past Due Total Carried at Amortized Cost 1 Loans Accounted for Under the Fair Value Option 2 Total Loans and Leases December 31, 2019 Commercial & Industrial Agriculture $ 8,941 $ — $ — $ — $ 8,941 $ 396 $ 9,337 Funeral Home & Cemetery 14,086 — — — 14,086 12,343 26,429 Healthcare 21,746 812 1,497 2,309 24,055 20,999 45,054 Independent Pharmacies 25,348 — — — 25,348 79,787 105,135 Registered Investment Advisors 42,421 — — — 42,421 56,769 99,190 Veterinary Industry 28,728 504 — 504 29,232 21,799 51,031 Other Industries 399,723 6,579 3,856 10,435 410,158 141,220 551,378 Total 540,993 7,895 5,353 13,248 554,241 333,313 887,554 Construction & Development Agriculture 44,571 — — — 44,571 — 44,571 Funeral Home & Cemetery 9,033 — — — 9,033 — 9,033 Healthcare 94,742 — — — 94,742 — 94,742 Independent Pharmacies 443 — — — 443 — 443 Registered Investment Advisors 2,404 — — — 2,404 — 2,404 Veterinary Industry 22,132 — — — 22,132 — 22,132 Other Industries 173,993 — — — 173,993 — 173,993 Total 347,318 — — — 347,318 — 347,318 Commercial Real Estate Agriculture 30,066 — — — 30,066 19,975 50,041 Funeral Home & Cemetery 53,426 1,817 — 1,817 55,243 58,171 113,414 Healthcare 125,622 — 4,498 4,498 130,120 115,887 246,007 Independent Pharmacies 8,070 930 — 930 9,000 17,013 26,013 Registered Investment Advisors 2,543 — — — 2,543 4,913 7,456 Veterinary Industry 65,928 1,727 1,088 2,815 68,743 76,154 144,897 Other Industries 361,394 4,585 — 4,585 365,979 93,537 459,516 Total 647,049 9,059 5,586 14,645 661,694 385,650 1,047,344 Commercial Land Agriculture 234,133 — — — 234,133 105,557 339,690 Total 234,133 — — — 234,133 105,557 339,690 Total $ 1,769,493 $ 16,954 $ 10,939 $ 27,893 $ 1,797,386 $ 824,520 $ 2,621,906 Net Deferred Costs $ 5,380 Loan and Leases, Net of unearned $ 2,627,286 1 Total loans and leases include $665.1 million of U.S. government guaranteed loans as of March 31, 2020, of which $12.0 million is greater than 90 days or more past due, $19.4 million is past due 30-89 days and $633.7 million are current. Total loans and leases include $622.6 million of U.S. government guaranteed loans as of December 31, 2019, of which $6.4 million is greater than 90 days or more past due, $13.6 million is past due 30-89 days and $602.6 million are current. 2 The Company measures the carrying value of the retained portion of loans sold at fair value under ASC Subtopic 825-10. See Note 9. Fair Value of Financial Instruments for additional information. Credit Quality Indicators The following tables presents asset quality indicators by portfolio segment and origination year. See Note 5. Loans and Leases Held for Investment and Credit Quality in the Company’s 2019 Form 10-K for additional discussion around the asset quality indicators that the Company uses to manage and monitor credit risk. Term Loans and Leases Amortized Cost Basis by Origination Year 2020 2019 2018 2017 2016 Prior Revolving Loans Amortized Cost Basis Revolving Loans Converted to Term Total 1,2 March 31, 2020 Commercial & Industrial Risk Grades 1 - 4 $ 71,188 $ 260,917 $ 68,136 $ 44,091 $ 12,455 $ 5,108 $ 99,612 $ 627 $ 562,134 Risk Grade 5 — 6,770 14,554 31 — 313 8,201 79 29,948 Risk Grades 6 - 8 — 3,300 10,968 3,852 — 481 942 — 19,543 Total 71,188 270,987 93,658 47,974 12,455 5,902 108,755 706 611,625 Construction & Development Risk Grades 1 - 4 18,172 141,380 138,387 43,656 11,128 449 2,175 — 355,347 Risk Grade 5 — — 7,788 8,758 — — — — 16,546 Risk Grades 6 - 8 — — — 704 — — — — 704 Total 18,172 141,380 146,175 53,118 11,128 449 2,175 — 372,597 Commercial Real Estate Risk Grades 1 - 4 56,428 160,097 119,640 178,714 84,876 51,762 1,817 172 653,506 Risk Grade 5 — — 14,256 7,767 22,351 5,098 200 — 49,672 Risk Grades 6 - 8 — — — 8,246 9,822 4,400 — — 22,468 Total 56,428 160,097 133,896 194,727 117,049 61,260 2,017 172 725,646 Commercial Land Risk Grades 1 - 4 5,626 31,404 54,474 55,682 66,166 52,576 — — 265,928 Risk Grade 5 — — — — — — — — — Risk Grades 6 - 8 — — 4 — — 4,334 — — 4,338 Total 5,626 31,404 54,478 55,682 66,166 56,910 — — 270,266 Total $ 151,414 $ 603,868 $ 428,207 $ 351,501 $ 206,798 $ 124,521 $ 112,947 $ 878 $ 1,980,134 Total 1,2 December 31, 2019 Commercial & Industrial Risk Grades 1 - 4 $ 510,508 Risk Grade 5 32,462 Risk Grades 6 - 8 11,271 Total 554,241 Construction & Development Risk Grades 1 - 4 331,135 Risk Grade 5 15,477 Risk Grades 6 - 8 706 Total 347,318 Commercial Real Estate Risk Grades 1 - 4 599,298 Risk Grade 5 41,573 Risk Grades 6 - 8 20,823 Total 661,694 Commercial Land Risk Grades 1 - 4 227,377 Risk Grade 5 — Risk Grades 6 - 8 6,756 Total 234,133 Total $ 1,797,386 1 Total loans and leases include $665.1 million of U.S. government guaranteed loans as of March 31, 2020, segregated by risk grade as follows: Risk Grades 1 – 4 = $584.5 million, Risk Grade 5 = $50.0 million, Risk Grades 6 – 8 = $30.6 million. As of December 31, 2019, total loans and leases include $622.6 million of U.S. government guaranteed loans, segregated by risk grade as follows: Risk Grades 1 – 4 = $556.8 million, Risk Grade 5 = $42.7 million, Risk Grades 6 – 8 = $23.1 million. Total loans and leases exclude loans accounted for under the fair value option. 2 Excludes $831.4 million and $824.5 million of loans accounted for under the fair value option as of March 31, 2020 and December 31, 2019, respectively. Nonaccrual Loans and Leases As of March 31, 2020 and December 31, 2019 there were no loans greater than 90 days past due and still accruing. There was no interest income recognized on nonaccrual loans and leases during the three month period ended March 31, 2020 or March 31, 2019. All nonaccrual loans and leases are included in the held for investment portfolio. Accrued interest receivable on loans totaled $20.8 million and $19.8 million at March 31, 2020 and December 31, 2019, respectively, and is included in other assets in the accompany consolidated balance sheets. Nonaccrual loans and leases as of March 31, 2020 and December 31, 2019 are as follows: March 31, 2020 Loan Balance 1 Guaranteed Balance Unguaranteed Balance Unguaranteed Exposure with No ACL Commercial & Industrial Agriculture $ 1 $ 1 $ — $ — Healthcare 2,099 1,905 194 — Independent Pharmacies 4,424 3,318 1,106 — Veterinary Industry 481 481 — — Other Industries 9,217 7,181 2,036 — Total 16,222 12,886 3,336 — Commercial Real Estate Healthcare 4,498 1,254 3,244 1,841 Independent Pharmacies 822 698 124 — Veterinary Industry 2,770 2,143 627 — Other Industries 5,439 4,079 1,360 — Total 13,529 8,174 5,355 1,841 Commercial Land Agriculture 4,337 3,405 932 32 Total 4,337 3,405 932 32 Total $ 34,088 $ 24,465 $ 9,623 $ 1,873 December 31, 2019 Loan Balance 1 Guaranteed Balance Unguaranteed Balance Commercial & Industrial Agriculture $ 269 $ 215 $ 54 Healthcare 2,309 1,931 378 Veterinary Industry 504 504 — Other Industries 3,856 2,906 950 Total 6,938 5,556 1,382 Commercial Real Estate Healthcare 4,498 1,254 3,244 Independent Pharmacies 931 698 233 Veterinary Industry 2,816 2,178 638 Total 8,245 4,130 4,115 Commercial Land Agriculture 6,756 5,028 1,728 Total 6,756 5,028 1,728 Total $ 21,939 $ 14,714 $ 7,225 1 Excludes nonaccrual loans accounted for under the fair value option. See Note 9. Fair Value of Financial Instruments for additional information. The following table presents the amortized cost basis of collateral-dependent loans and leases, which are individually evaluated to determine expected credit losses, as of March 31, 2020: Total Collateral Dependent Loans Unguaranteed Portion March 31, 2020 Real Estate Business Assets Other Real Estate Business Assets Other Allowance for Credit Losses Commercial & Industrial Healthcare $ 1,188 $ 178 $ — $ 41 $ 3 $ — $ 44 Independent Pharmacies — 4,514 — — 1,196 — 1,177 Other Industries 4,586 2,267 2,148 1,363 557 148 1,067 Total 5,774 6,959 2,148 1,404 1,756 148 2,288 Commercial Real Estate Healthcare 1,821 — — 1,821 — — — Independent Pharmacies 826 — — 128 — — 4 Veterinary Industry 2,792 — — 649 — — 180 Other Industries 5,449 — — 1,371 — — 3 Total 10,888 — — 3,969 — — 187 Commercial Land Agriculture 4,359 — — 952 — — 328 Total 4,359 — — 952 — — 328 Total $ 21,021 $ 6,959 $ 2,148 $ 6,325 $ 1,756 $ 148 $ 2,803 Allowance for Credit Losses - Loans and Leases On January 1, 2020 the Company adopted ASC 326. Upon adoption, the Company’s maintains the ACL at levels management believes represents the future expected credit losses in the loan and lease portfolios as of the balance sheet date. See Note 1. Basis of Presentation for additional information around the Company’s methodology for estimating the ACL. See Note 1. Organization and Summary of Significant Accounting Policies and Note 5. Loans and Leases Held for Investment and Credit Quality in the Company’s 2019 Form 10-K for additional information related to the Company’s methodology for estimating the prior period allowance for credit losses under ASC 310. The following table details activity in the ACL by portfolio segment allowance for the periods presented: Three Months Ended Construction & Development Commercial Real Estate Commercial & Industrial Commercial Land Total March 31, 2020 Beginning Balance, prior to adoption of ASC 326 $ 2,732 $ 8,427 $ 15,757 $ 1,318 $ 28,234 Impact of adopting ASC 326 1,131 1,916 (4,561 ) 193 (1,321 ) Charge offs — (109 ) (2,345 ) (408 ) (2,862 ) Recoveries — 28 35 — 63 Provision 960 2,848 7,451 533 11,792 Ending Balance $ 4,823 $ 13,110 $ 16,337 $ 1,636 $ 35,906 March 31, 2019 Beginning Balance $ 2,042 $ 5,259 $ 6,524 $ 607 $ 14,432 Charge offs — — — — — Recoveries — 8 79 — 87 Provision 194 112 1,679 1,046 3,031 Ending Balance $ 2,236 $ 5,379 $ 8,282 $ 1,653 $ 17,550 During the three month period ended March 31, 2020, changes to the ACL were primarily related to the severity of forecasted unemployment rates as a result of the COVID-19 pandemic. Unemployment rates were forecasted for twelve months followed by a twelve-month straight-line reversion period. Additionally, the provision expense was impacted by loan and lease growth and net charge-offs during the period. The following tables represent the types of TDRs that were made during the periods presented: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 All Restructurings All Restructurings Number of Loans Recorded investment at period end Number of Loans Recorded investment at period end Extended Amortization Commercial Land Agriculture — $ — 1 $ 3,489 Commercial & Industrial Other Industries 1 973 — — Total Extend Amortization 1 973 1 3,489 Payment Deferral Commercial & Industrial Other Industries 2 1,487 — — Commercial Real Estate Healthcare — — 1 1,853 Other Industries 1 3,589 — — Total Payment Deferral 3 5,076 1 1,853 Total 4 $ 6,049 2 $ 5,342 Concessions made to improve a loan or lease’s performance have varying degrees of success. No TDRs that were modified within the twelve months ended March 31, 2020 and 2019 subsequently defaulted during the three months ended March 31, 2020 and 2019. The following tables detail the recorded allowance for loan and lease losses and the investment in loans and leases related to each portfolio segment, disaggregated on the basis of impairment evaluation methodology: December 31, 2019 Construction & Development Commercial Real Estate Commercial & Industrial Commercial Land Total 1,2 Allowance for loan and lease losses: Loans and leases individually evaluated for impairment $ 17 $ 2,067 $ 3,989 $ 748 $ 6,821 Loans and leases collectively evaluated for impairment 2,715 6,360 11,768 570 21,413 Total allowance for loan and lease losses $ 2,732 $ 8,427 $ 15,757 $ 1,318 $ 28,234 Loans and leases receivable: Loans and leases individually evaluated for impairment $ 719 $ 25,389 $ 14,052 $ 17,347 $ 57,507 Loans and leases collectively evaluated for impairment 346,599 636,305 540,189 216,786 1,739,879 Total loans and leases receivable $ 347,318 $ 661,694 $ 554,241 $ 234,133 $ 1,797,386 1 As of December 31, 2019, loans and leases receivable includes $622.6 million of U.S. government guaranteed loans, of which $36.0 million are considered impaired. 2 Loans and leases receivable exclude $824.5 million of loans accounted for under the fair value option. Loans and leases classified as impaired as of the dates presented are summarized in the following tables. December 31, 2019 Recorded Investment Guaranteed Balance Unguaranteed Exposure Commercial & Industrial Agriculture $ 367 $ 215 $ 152 Healthcare 3,760 1,931 1,829 Veterinary Industry 504 504 — Other Industries 9,421 5,348 4,073 Total 14,052 7,998 6,054 Construction & Development Healthcare 719 530 189 Total 719 530 189 Commercial Real Estate Healthcare 12,677 5,101 7,576 Independent Pharmacies 933 698 235 Veterinary Industry 5,907 4,707 1,200 Other Industries 5,872 4,079 1,793 Total 25,389 14,585 10,804 Commercial Land Agriculture 17,347 12,898 4,449 Total 17,347 12,898 4,449 Total $ 57,507 $ 36,011 $ 21,496 The following table presents evaluated balances of loans and leases classified as impaired at the dates presented that carried an associated reserve as compared to those with no reserve. The recorded investment includes accrued interest and net deferred loan and lease fees or costs. December 31, 2019 Recorded Investment With a Recorded Allowance With No Recorded Allowance Total Unpaid Principal Balance Related Allowance Recorded Commercial & Industrial Agriculture $ 362 $ 5 $ 367 $ 378 $ 95 Healthcare 3,760 — 3,760 4,109 975 Veterinary Industry 504 — 504 672 4 Other Industries 9,421 — 9,421 9,725 2,915 Total 14,047 5 14,052 14,884 3,989 Construction & Development Healthcare 719 — 719 706 17 Total 719 — 719 706 17 Commercial Real Estate Healthcare 10,835 1,842 12,677 12,602 1,579 Independent Pharmacies 933 — 933 930 88 Veterinary Industry 5,907 — 5,907 6,615 311 Other Industries 5,611 261 5,872 5,697 89 Total 23,286 2,103 25,389 25,844 2,067 Commercial Land Agriculture 17,347 — 17,347 17,399 748 Total 17,347 — 17,347 17,399 748 Total Impaired Loans and Leases $ 55,399 $ 2,108 $ 57,507 $ 58,833 $ 6,821 The following table presents the average recorded investment of impaired loans and leases for each period presented and interest income recognized during the period in which the loans and leases were considered impaired. Three Months Ended March 31, 2019 Average Balance Interest Income Recognized Commercial & Industrial Agriculture $ 6 $ — Healthcare 4,492 29 Veterinary Industry 632 1 Other Industries 3,532 17 Total 8,662 47 Commercial Real Estate Healthcare 9,772 101 Veterinary Industry 6,282 41 Other Industries 1,588 — Total 17,642 142 Commercial Land Agriculture 21,505 196 Total 21,505 196 Total $ 47,809 $ 385 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Leases | Note 6. Leases Lessor Equipment Leasing The Company purchases new equipment for the purpose of leasing such equipment to customers within its verticals. Equipment purchased to fulfill commitments to commercial renewable energy projects is rented out under operating leases while leases of equipment outside of the renewable energy vertical are generally direct financing leases. Accordingly, leased assets under operating leases are included in premises and equipment while leased assets under direct financing leases are included in loans and leases held for investment. Direct Financing Leases Interest income on direct financing leases is recognized when earned. Unearned interest is recognized over the lease term on a basis which results in a constant rate of return on the unrecovered lease investment. The term of each lease is generally 3-7 years which is consistent with the useful life of the equipment with no residual value. The gross lease payments receivable and the net investment included in accounts receivable for such leases are as follows: March 31, 2020 December 31, 2019 Gross direct finance lease payments receivable $ 13,197 $ 13,959 Less – unearned interest (2,334 ) (2,562 ) Net investment in direct financing leases $ 10,863 $ 11,397 Future minimum lease payments under finance leases are as follows: As of March 31, 2020 Amount 2020 $ 2,367 2021 2,928 2022 2,699 2023 2,259 2024 1,635 Thereafter 1,309 Total $ 13,197 Interest income of $233 thousand and $234 thousand was recognized in the three months ended March 31, 2020 and 2019, respectively. Operating Leases The term of each operating lease is generally 10 to 15 years. The Company retains ownership of the equipment and associated tax benefits such as investment tax credits and accelerated depreciation. At the end of the lease term, the lessee has the option to renew the lease for two additional terms or purchase the equipment at the then current fair market value. Rental revenue from operating leases is recognized on a straight-line basis over the term of the lease. Rental equipment is recorded at cost and depreciated to an estimated residual value on a straight-line basis over the estimated useful life. The useful lives generally range from 20 to 25 years and residual values generally range from 20% to 50%, however, they are subject to periodic evaluation. Changes in useful lives or residual values will impact depreciation expense and any gain or loss from the sale of used equipment. The estimated useful lives and residual values of the Company's leasing equipment are based on industry disposal experience and the Company's expectations for future sale prices. If the Company decides to sell or otherwise dispose of rental equipment, it is carried at the lower of cost or fair value less costs to sell or dispose. Repair and maintenance costs that do not extend the lives of the rental equipment are charged to direct operating expenses at the time the costs are incurred. As of March 31, 2020 and December 31, 2019, the Company had a net investment of $141.8 million and $144.3 million, respectively, in assets included in premises and equipment that are subject to operating leases. Of the net investment, the gross balance of the assets was $164.3 million as of March 31, 2020 and December 31, 2019 and accumulated depreciation was $ 22.5 Lease income of $2.4 million and $2.3 million was recognized in the three months ended March 31, 2020 and 2019, respectively. A maturity analysis of future minimum lease payments under non-cancelable operating leases is as follows: As of March 31, 2020 Amount 2020 $ 7,060 2021 9,052 2022 9,044 2023 9,075 2024 8,808 Thereafter 40,110 Total $ 83,149 |
Servicing Assets
Servicing Assets | 3 Months Ended |
Mar. 31, 2020 | |
Transfers And Servicing [Abstract] | |
Servicing Assets | Note 7. Servicing Assets Loans serviced for others are not included in the accompanying condensed consolidated balance sheets. The unpaid principal balances of loans serviced for others requiring recognition of a servicing asset were $2.22 billion and $2.26 billion at March 31, 2020 and December 31, 2019, respectively. The unpaid principal balance for all loans serviced for others was $2.98 billion and $2.97 billion at March 31, 2020 and December 31, 2019, respectively. The following summarizes the activity pertaining to servicing rights: Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 35,365 $ 47,641 Additions, net 2,859 723 Fair value changes: Due to changes in valuation inputs or assumptions (2,039 ) (524 ) Decay due to increases in principal paydowns or runoff (2,653 ) (3,516 ) Balance at end of period $ 33,532 $ 44,324 The fair value of servicing rights was determined using a weighted average discount rate of 13.0% on March 31, 2020 and 14.7% on March 31, 2019. The fair value of servicing rights was determined using a weighted average prepayment speed of 17.9% on March 31, 2020 and 13.1% on March 31, 2019, depending on the stratification of the specific right. Changes to fair value are reported in loan servicing asset revaluation within the consolidated statements of income. The fair value of servicing rights is highly sensitive to changes in underlying assumptions. Changes in prepayment speed assumptions typically have the most significant impact on the fair value of servicing rights. Generally, as interest rates rise on variable rate loans, loan prepayments increase due to an increase in refinance activity, which results in a decrease in the fair value of servicing assets, however, weakening economic conditions or significant declines in interest rates can also increase loan prepayment activity. Measurement of fair value is limited to the conditions existing and the assumptions used as of a particular point in time, and those assumptions may not be appropriate if they are applied at a different time. |
Borrowings
Borrowings | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Borrowings | Note 8. Borrowings Total outstanding borrowings consisted of the following: March 31, 2020 December 31, 2019 Borrowings In 2019, the Company renewed a revolving line of credit issued in 2017. The line of credit is unsecured and accrues interest at 30-day LIBOR plus 1.15% for a term of 13 months. Payments are interest only with all principal and accrued interest due on October 20, 2020. The terms of this loan require the Company to maintain minimum capital and debt service coverage ratios. This $50 million line of credit has been fully advanced and there is no available credit remaining at March 31, 2020. $ 50,000 $ — In October 2017, the Company entered into a financing lease of $19 thousand with an unaffiliated equipment lease company, secured by fitness equipment which is included in other assets on the consolidated balance sheet. Payments are principal and interest due monthly starting December 15, 2017 over a term of 60 months. At the end of the lease term there is a $1.00 bargain purchase option. As of January 1, 2019, this borrowing was revised in accordance with ASU 2016-02. 12 14 Total borrowings $ 50,012 $ 14 The Company may purchase federal funds through unsecured federal funds lines of credit with various correspondent banks, which totaled $72.5 million as of March 31, 2020 and December 31, 2019. These lines are intended for short-term borrowings and are subject to restrictions limiting the frequency and terms of advances. These lines of credit are payable on demand and bear interest based upon the daily federal funds rate. The Company had no outstanding balances on the lines of credit as of March 31, 2020 and December 31, 2019. The Company has entered into a repurchase agreement with a third party for $5.0 million as of March 31, 2020 and December 31, 2019. At the time the Company enters into a transaction with the third party, the Company must transfer securities or other assets against the funds received. The terms of the agreement are set at market conditions at the time the Company enters into such transaction. The Company had no outstanding balance on the repurchase agreement as of March 31, 2020 and December 31, 2019. On June 18, 2018, the Company entered into a borrowing agreement with the Federal Home Loan Bank of Atlanta. These borrowings must be secured with eligible collateral approved by the Federal Home Loan Bank of Atlanta. At March 31, 2020 and December 31, 2019, the Company had approximately $1.20 billion and $1.14 billion, respectively, in borrowing capacity available under these agreements. There is no collateral pledged and no advances outstanding as of March 31, 2020 and December 31, 2019. The Company may borrow funds through the Federal Reserve Bank’s discount window. These borrowings are secured by a blanket floating lien on qualifying loans with a balance of $565.8 million and $526.8 million as of March 31, 2020 and December 31, 2019, respectively. At March 31, 2020 and December 31, 2019, the Company had approximately $309.1 million and $294.5 million, respectively, in borrowing capacity available under these arrangements with no outstanding balance as of March 31, 2020 and December 31, 2019. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Note 9 . Fair Value of Financial Instruments Fair Value Hierarchy There are three levels of inputs in the fair value hierarchy that may be used to measure fair value. Financial instruments are considered Level 1 when valuation can be based on quoted prices in active markets for identical assets or liabilities. Level 2 financial instruments are valued using quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or models using inputs that are observable or can be corroborated by observable market data of substantially the full term of the assets or liabilities. Financial instruments are considered Level 3 when their values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable and when determination of the fair value requires significant management judgment or estimation. Recurring Fair Value The following sections provide a description of the valuation methodologies used for instruments measured at fair value on a recurring basis, as well as the general classification of such instruments pursuant to the fair value hierarchy: Investment securities: Where quoted prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities would include highly liquid government bonds, mortgage products and exchange traded equities. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics, discounted cash flow or at net asset value per share. Level 2 securities would include U.S. government agency securities, mortgage-backed securities, obligations of states and political subdivisions and certain corporate, asset backed mutual fund and other securities. In certain cases where there is limited activity or less transparency around inputs to the valuation, securities are classified within Level 3 of the valuation hierarchy. Loans held for sale: The fair values of loans held for sale are determined by discounting estimated cash flows using interest rates approximating prevailing market rates for similar loans adjusted to reflect the inherent credit risk. Loans held for investment: The fair values of loans held for investment are typically determined based on discounted cash flow analyses using market-based interest rate spreads. Discounted cash flow analyses are adjusted, as appropriate, to reflect current market conditions and borrower-specific credit risk. If the loan is collateral dependent, the fair value is determined based on the difference between the fair value of the collateral and the amortized cost basis of the loan as of the measurement date. Fair value of the loan’s collateral is determined by appraisals, independent valuation, or management’s estimation of fair value which is then adjusted for the cost related to liquidation of the collateral. Servicing assets: Servicing rights do not trade in an active, open market with readily observable prices. While sales of servicing rights do occur, the precise terms and conditions typically are not readily available. Accordingly, the Company estimates the fair value of servicing rights using discounted cash flow models incorporating numerous assumptions from the perspective of a market participant including servicing income, servicing costs, market discount rates and prepayment speeds. Due to the nature of the valuation inputs, servicing rights are classified within Level 3 of the valuation hierarchy. Mutual fund: The following mutual fund is registered with the Securities and Exchange Commission as a closed-end, non-diversified management investment company and operates as an interval fund. The fund primarily invests in the unguaranteed portion of SBA504 First Lien Loans secured by owner-occupied commercial real estate. This investment is valued using quoted prices in markets that are not active and is classified as Level 2 within the valuation hierarchy. Equity warrant assets: Fair value measurements of equity warrant assets of private companies are priced based on a Black-Scholes option pricing model to estimate the asset value by using stated strike prices, option expiration dates, risk-free interest rates and option volatility assumptions. Option volatility assumptions used in the Black-Scholes model are based on public companies that operate in similar industries as the companies in our private company portfolio. Option expiration dates are modified to account for estimates to actual life relative to stated expiration. Values are further adjusted for a general lack of liquidity due to the private nature of the associated underlying company. The Company classifies equity warrant assets within Level 3 of the valuation hierarchy. The tables below present the recorded amount of assets and liabilities measured at fair value on a recurring basis. March 31, 2020 Total Level 1 Level 2 Level 3 Investment securities available-for-sale US treasury securities $ 5,043 $ — $ 5,043 $ — US government agencies 23,079 — 23,079 — Mortgage-backed securities 537,291 — 537,291 — Municipal bonds 1 8,755 — 8,662 93 Loans held for sale 19,151 — — 19,151 Loans held for investment 831,426 — — 831,426 Servicing assets 2 33,532 — — 33,532 Mutual fund 2,141 — 2,141 — Equity warrant assets 3 702 — — 702 Total assets at fair value $ 1,461,120 $ — $ 576,216 $ 884,904 December 31, 2019 Total Level 1 Level 2 Level 3 Investment securities available-for-sale US treasury securities $ 5,015 $ — $ 5,015 $ — US government agencies 22,779 — 22,779 — Mortgage-backed securities 503,297 — 503,297 — Municipal bonds 1 8,954 — 8,862 92 Loans held for sale 16,198 — — 16,198 Loans held for investment 824,520 — — 824,520 Servicing assets 2 35,365 — — 35,365 Mutual fund 2,206 — 2,206 — Equity warrant assets 3 570 — — 570 Total assets at fair value $ 1,418,904 $ — $ 542,159 $ 876,745 1 During the three months ended March 31, 2020, the Company recorded a fair value adjustment gain of $1 thousand. During the three months ended March 31, 2019, the Company sold $900 thousand of a municipal bond to a third party and recorded a fair value adjustment loss of $9 thousand. 2 See Note 7 for a rollforward of recurring Level 3 fair values for servicing assets. 3 During the three months ended March 31, 2020, the Company entered into equity warrant assets with a fair value of $164 thousand at the time of issuance and recorded net losses on derivative instruments of $32 thousand. During the three months ended March 31, 2019, the Company recorded net gains on derivative instruments of $255 thousand. Fair Value Option The Company elects to account for retained participating interests of government guaranteed loans under the fair value option in order to align the accounting presentation with the Company’s viewpoint of the economics of the loans. Interest income on loans accounted for under the fair value option is recognized in loans and fees on loans on the Company’s consolidated statements of income. There were no loans accounted for under the fair value option that were 90 days or more past due and still accruing interest at March 31, 2020 or December 31, 2019. The unpaid principal balance of unguaranteed exposure for nonaccruals was $12.2 million and $10.7 million at March 31, 2020 and December 31, 2019, respectively. The following tables provide more information about the fair value carrying amount and the unpaid principal outstanding of loans accounted for under the fair value option at March 31, 2020 and December 31, 2019. March 31, 2020 Total Loans Nonaccruals 90 Days or More Past Due Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Option Elections Loans held for sale $ 19,151 $ 20,056 $ (905 ) $ — $ — $ — $ — $ — $ — Loans held for investment 831,426 858,577 (27,151 ) 60,558 65,303 (4,745 ) 39,102 40,876 (1,774 ) $ 850,577 $ 878,633 $ (28,056 ) $ 60,558 $ 65,303 $ (4,745 ) $ 39,102 $ 40,876 $ (1,774 ) December 31, 2019 Total Loans Nonaccruals 90 Days or More Past Due Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Option Elections Loans held for sale $ 16,198 $ 17,230 $ (1,032 ) $ — $ — $ — $ — $ — $ — Loans held for investment 824,520 842,456 (17,936 ) 49,739 54,370 (4,631 ) 26,644 28,137 (1,493 ) $ 840,718 $ 859,686 $ (18,968 ) $ 49,739 $ 54,370 $ (4,631 ) $ 26,644 $ 28,137 $ (1,493 ) The following table presents the net gains (losses) from changes in fair value. Three Months Ended March 31, Gains (Losses) on Loans Accounted for under the Fair Value Option 2020 2019 Loans held for sale $ 120 $ (351 ) Loans held for investment (10,758 ) 2,434 $ (10,638 ) $ 2,083 Losses related to borrower-specific credit risk were $922 thousand and $522 thousand for the three months ended March 31, 2020 and 2019, respectively. The following tables summarize the activity pertaining to loans accounted for under the fair value option. Three Months Ended March 31, Loans held for sale 2020 2019 Balance at beginning of period $ 16,198 $ 17,745 Issuances 3,045 13,635 Fair value changes 120 (351 ) Sales — (5,700 ) Settlements (212 ) (36 ) Balance at end of period $ 19,151 $ 25,293 Three Months Ended March 31, Loans held for investment 2020 2019 Balance at beginning of period $ 824,520 $ 885,527 Issuances 61,611 30,108 Fair value changes (10,758 ) 2,434 Settlements (43,947 ) (49,415 ) Balance at end of period $ 831,426 $ 868,654 Non-recurring Fair Value The following sections provide a description of the valuation methodologies used for instruments measured at fair value on a non-recurring basis, as well as the general classification of such instruments pursuant to the fair value hierarchy: Collateral dependent loans : Loans are considered collateral dependent when the Company has determined that foreclosure of the collateral is probable or when a borrower is experiencing financial difficulty and the loan is expected to be repaid substantially through the operation or sale of collateral. A collateral dependent loan’s ACL is measured based on the difference between the fair value of the collateral and the amortized cost basis of the loan as of the measurement date. Fair value of the loan’s collateral is determined by appraisals, independent valuation, or management’s estimation of fair value which is then adjusted for the cost related to liquidation of the collateral. Collateral dependent loans are generally classified as Level 3 based on management’s judgment and estimation. Foreclosed assets: Foreclosed real estate is adjusted to fair value less selling costs upon transfer of the loans to foreclosed real estate. Subsequently, foreclosed real estate is carried at the lower of carrying value or fair value less selling costs. Fair value is based upon independent market prices, appraised values of the collateral or management’s estimation of the value of the collateral. Given the lack of observable market prices for identical properties and market discounts applied to appraised values, the Company generally classifies foreclosed assets as nonrecurring Level 3. Equity security investment with a non-readily determinable fair value: The following equity security investment is measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. When an observable price change in an orderly transaction occurs, the investment is classified as nonrecurring Level 1 within the valuation hierarchy. The tables below present the recorded amount of assets and liabilities measured at fair value on a non-recurring basis. March 31, 2020 Total Level 1 Level 2 Level 3 Collateral dependent loans $ 2,349 $ — $ — $ 2,349 Foreclosed assets 6,744 — — 6,744 Total assets at fair value $ 9,093 $ — $ — $ 9,093 December 31, 2019 Total Level 1 Level 2 Level 3 Collateral dependent loans $ 1,245 $ — $ — $ 1,245 Foreclosed assets 5,612 — — 5,612 Equity security investment with a non-readily determinable fair value 8,738 8,738 — — Total assets at fair value $ 15,595 $ 8,738 $ — $ 6,857 Level 3 Analysis For Level 3 assets and liabilities measured at fair value on a recurring or non-recurring basis as of March 31, 2020 and December 31, 2019 the significant unobservable inputs used in the fair value measurements were as follows: March 31, 2020 Level 3 Assets with Significant Unobservable Inputs Fair Value Valuation Technique Significant Unobservable Inputs Range Recurring fair value Municipal bond $ 93 Discounted expected cash flows Discount rate Prepayment speed 4.2% 5.0% Loans held for sale $ 19,151 Discounted expected cash flows Discount rate Prepayment speed 7.1% to 15.4% WAVG 17.9% Loans held for investment $ 831,426 Discounted expected cash flows Discounted appraisals Loss rate Discount rate Prepayment speed Appraisal adjustments 0.0% to 82.5% (WAVG 1.8%) 7.1% to 15.4% WAVG 17.9% 10% to 50% Equity warrant assets $ 702 Black-Scholes option pricing model Volatility Risk-free interest rate Marketability discount Remaining life 24.7 to 85.4% 0.7% 20.0% 7-10 years Non-recurring fair value Collateral dependent loans $ 2,349 Discounted appraisals Appraisal adjustments (1) 10.0% to 55.0% Foreclosed assets $ 6,744 Discounted appraisals Appraisal adjustments (1) 4.0% to 14.5% December 31, 2019 Level 3 Assets with Significant Unobservable Inputs Fair Value Valuation Technique Significant Unobservable Inputs Range Recurring fair value Municipal bond $ 92 Discounted expected cash flows Discount rate Prepayment speed 4.6% 5.0% Loans held for sale $ 16,198 Discounted expected cash flows Discount rate Prepayment speed 7.7% to 21.4% WAVG 13.1% Loans held for investment $ 824,520 Discounted expected cash flows Discounted appraisals Loss rate Discount rate Prepayment speed Appraisal adjustments 0.0% to 10.9% (WAVG 1.3%) 7.7% to 21.4% WAVG 13.1% 10.0% to 70.0% Equity warrant assets $ 570 Black-Scholes option pricing model Volatility Risk-free interest rate Marketability discount Remaining life 21.0-75.0% 1.90% 20.0% 8-10 years Non-recurring fair value Collateral dependent loans $ 1,245 Discounted appraisals Appraisal adjustments (1) 10.0% to 57.0% Foreclosed assets $ 5,612 Discounted appraisals Appraisal adjustments (1) 10.0% to 37.0% (1) Appraisals may be adjusted by management for customized discounting criteria, estimated sales costs, and proprietary qualitative adjustments. Estimated Fair Value of Other Financial Instruments GAAP also requires disclosure of the fair value of financial instruments carried at book value on the consolidated balance sheets. The carrying amounts and estimated fair values of the Company’s financial instruments not measured at fair value on a recurring or non-recurring basis are as follows: March 31, 2020 Carrying Amount Quoted Price In Active Markets for Identical Assets /Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Financial assets Cash and due from banks $ 256,824 $ 256,824 $ — $ — $ 256,824 Federal funds sold 158,226 158,226 — — 158,226 Certificates of deposit with other banks 7,250 7,755 — — 7,755 Loans held for sale 976,899 — — 1,044,207 1,044,207 Loans and leases, net of allowance for credit losses on loans and leases 1,950,159 — — 2,053,965 2,053,965 Financial liabilities Deposits 4,642,148 — 4,717,676 — 4,717,676 Borrowings 50,012 — — 50,301 50,301 December 31, 2019 Carrying Amount Quoted Price In Active Markets for Identical Assets /Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Financial assets Cash and due from banks $ 126,752 $ 126,752 $ — $ — $ 126,752 Federal funds sold 96,787 96,787 — — 96,787 Certificates of deposit with other banks 7,250 7,568 — — 7,568 Loans held for sale 950,249 — — 1,004,135 1,004,135 Loans and leases, net of allowance for credit losses on loans and leases 1,774,532 — — 1,822,569 1,822,569 Financial liabilities Deposits 4,229,122 — 4,213,657 — 4,213,657 Borrowings 14 — — 14 14 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Commitments and Contingencies | Note 10. Commitments and Contingencies Litigation In the normal course of business the Company is involved in various legal proceedings. Management believes that the outcome of such proceedings will not materially affect the financial position, results of operations or cash flows of the Company. Financial Instruments with Off-balance-sheet Risk The Company is party to financial instruments with off-balance-sheet risk in the normal course of business to meet the financing needs of its customers. These financial instruments include commitments to extend credit and standby letters of credit. These instruments involve, to varying degrees, credit risk in excess of the amount recognized in the balance sheet. The Company’s exposure to credit loss in the event of nonperformance by the other party to the financial instrument for commitments to extend credit and standby letters of credit is represented by the contractual amount of those instruments. The Company uses the same credit policies in making commitments and conditional obligations as for on-balance-sheet instruments. A summary of the Company’s commitments is as follows: March 31, 2020 December 31, 2019 Commitments to extend credit $ 1,732,944 $ 1,834,449 Standby letters of credit 27,512 25,532 Operating lease commitments 803 — Total unfunded off-balance-sheet credit risk $ 1,761,259 $ 1,859,981 Commitments to extend credit are agreements to lend to a customer as long as there is no violation of any condition established in the contract. Commitments generally have fixed expiration dates or other termination clauses and may require payment of a fee. Since many of the commitments are expected to expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements. The Company evaluates each customer’s creditworthiness on a case-by-case basis. The amount of collateral obtained, if deemed necessary by the Company upon extension of credit, is based on management’s credit evaluation of the party. Collateral held varies, but may include accounts receivable, inventory, property and equipment, residential real estate and income-producing commercial properties. In 2012, the Company began issuing commitment letters after approval of the loan by the Credit Department. Commitment letters generally expire ninety days after issuance. Standby letters of credit are conditional commitments issued by the Company to guarantee the performance of a customer to a third party. Those guarantees are primarily issued to support public and private borrowing arrangements. The credit risk involved in issuing letters of credit is essentially the same as that involved in extending loan facilities to customers. Collateral held varies as specified above and is required in instances which the Company deems necessary. Operating lease commitments are non-cancelable operating lease agreements for real property entered by the Company during the period which have not commenced. As of March 31, 2020 and December 31, 2019, the Company had unfunded commitments to provide capital contributions for on-balance-sheet investments in the amount of $16.9 million. Concentrations of Credit Risk Although the Company is not subject to any geographic concentrations, a substantial amount of the Company’s loans, leases, and commitments to extend credit have been granted to customers in the agriculture, healthcare and veterinary verticals. The concentrations of credit by type of loan are set forth in Note 5. The distribution of commitments to extend credit approximates the distribution of loans outstanding. The Company does not have a significant number of credits to any single borrower or group of related borrowers whereby their retained unguaranteed exposure exceeds $7.5 million, except for 30 relationships that have a retained unguaranteed exposure of $325.7 million of which $217.4 million of the unguaranteed exposure has been disbursed. Additionally, the Company has future minimum lease payments due under non-cancelable operating leases totaling $83.1 million, of which $59.8 million is due from four relationships. The Company from time-to-time may have cash and cash equivalents on deposit with financial institutions that exceed federally-insured limits. |
Stock Plans
Stock Plans | 3 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Plans | Note 1 1 . Stock Plans On March 20, 2015, the Company adopted the 2015 Omnibus Stock Incentive Plan which replaced the previously existing Amended Incentive Stock Option Plan and Nonstatutory Stock Option Plan. Subsequently on May 24, 2016, the 2015 Omnibus Stock Incentive Plan was amended to authorize awards covering a maximum of 7,000,000 common voting shares and has an expiration date of March 20, 2025. On May 15, 2018, the Amended and Restated 2015 Omnibus Stock Incentive Plan was amended to authorize awards covering a maximum of 8,750,000 common voting shares. Options or restricted shares granted under the Amended and Restated 2015 Omnibus Stock Incentive Plan (the "Plan") expire no more than 10 years from the date of grant. Exercise prices under the Plan are set by the Board of Directors at the date of grant, but shall not be less than 100% of fair market value of the related stock at the date of the grant. Options vest over a minimum of three years from the date of the grant. Restricted stock grants vest in equal installments ranging from immediate vesting to over a seven year period from the date of the grant. Market Restricted Stock Units also have a restriction based on the passage of time and non-market-related performance criteria, but also have a restriction based on market price criteria related to the Company’s share price closing at or above a specified price defined at time of grant. Stock Options There were no stock options granted during the three months ended March 31, 2020. At March 31, 2020, unrecognized compensation costs relating to stock options amounted to $3.7 million which will be recognized over a weighted average period of 2.35 years. Restricted Stock Restricted stock awards are authorized in the form of restricted stock awards or units ("RSU"s) and restricted stock awards or units with a market price condition ("Market RSU"s). RSUs have a restriction based on the passage of time and may also have a restriction based on a non-market-related performance criteria. The fair value of the RSUs is based on the closing price on the date of the grant. Market RSUs also have a restriction based on the passage of time and non-market-related performance criteria, but also have a restriction based on market price criteria related to the Company’s share price closing at or above a specified price ranging from $34.00 to $55.00 per share for at least twenty (20) consecutive trading days at any time prior to expiration date. The amount of Market RSUs earned will not exceed 100% of the Market RSUs awarded. The fair value of the Market RSUs and the implied service period is calculated using the Monte Carlo simulation method. For the three months ended March 31, 2020, 483,331 RSUs were granted with a weighted average grant date fair value of $17.98. Of the RSUs granted, 447,273 were awarded in connection with annual long term incentive stock compensation. At March 31, 2020, unrecognized compensation costs relating to RSUs amounted to $16.2 million which will be recognized over a weighted average period of 4.30 years. There were no Market RSUs granted during the three months ended March 31, 2020. At March 31, 2020, unrecognized compensation costs relating to Market RSUs amounted to $12.6 million which will be recognized over a weighted average period of 2.94 years. |
Significant Equity Method Inves
Significant Equity Method Investments | 3 Months Ended |
Mar. 31, 2020 | |
Equity Method Investments And Joint Ventures [Abstract] | |
Significant Equity Method Investments | Note 12. Significant Equity Method Investments In accordance with Rule 10-01(b)(1) of Regulation S-X, the Company must assess whether any of its equity method investments are significant equity method investments. In evaluating the significance of these investments, the Company performed the income test and the investment test described in S-X 3-05 and S-X 1-02(w). Rule 10-01(b)(1) of Regulation S-X requires summarized financial information in a quarterly report if any of the two tests exceeds 20%. Under the income test, the Company’s proportionate share of its equity method investees' aggregated net losses exceeded the applicable threshold of 20% and is accordingly required to provide summarized financial information for these investees for all periods presented in this Form 10-Q. The following table provides summarized balance sheet information for the Company’s equity method investments as of March 31, 2020 and December 31, 2019. The Company’s equity method investments are included in the other assets line on the consolidated balances sheet and are largely concentrated in new or emerging financial service technology companies. March 31, 2020 December 31, 2019 Balance sheet data Current assets $ 52,228 $ 56,710 Noncurrent assets 176,472 162,304 Total assets $ 228,700 $ 219,014 Current liabilities $ 20,183 $ 19,910 Noncurrent liabilities 664 683 Total liabilities 20,847 20,593 Equity interests 207,853 198,421 Total liabilities and equity $ 228,700 $ 219,014 The following table provides summarized income statement information for the Company’s equity method investments for the three months ended March 31, 2020 and 2019. Three Months Ended March 31, 2020 2019 Summary of operations Total revenues $ 15,792 $ 13,389 Net loss (16,433 ) (7,120 ) |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
General | General In the opinion of management, all adjustments necessary for a fair presentation of the financial position and results of operations for the periods presented have been included, and all intercompany transactions have been eliminated in consolidation. Results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2020. The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities Exchange Commission on February 27, 2020 (SEC File No. 001-37497) (the "2019 Annual Report"). A summary description of the significant accounting policies followed by the Company is set forth in Note 1 of the Notes to Consolidated Financial Statements in the Company’s 2019 Annual Report. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes in the Company's 2019 Annual Report. The preparation of financial statements in conformity with United States generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. Amounts in all tables in the Notes to Unaudited Condensed Consolidated Financial Statements have been presented in thousands, except percentage, time period, stock option, share and per share data or where otherwise indicated. |
Business Segments | Business Segments Management has determined that the Company has one significant operating segment, which is providing a lending platform for small businesses nationwide. In determining the appropriateness of segment definition, the Company considers the materiality of a potential segment, the components of the business about which financial information is available, and components for which management regularly evaluates relative to resource allocation and performance assessment. |
Reclassifications | Reclassifications Certain reclassifications have been made to the prior period’s consolidated financial statements to place them on a comparable basis with the current year. Net income and shareholders’ equity previously reported were not affected by these reclassifications. Current period reclassifications were primarily related to fair value presentation requirements for loans in which the fair value option had previously been elected and included a reclassification of amounts representing the credit component of the fair value discount that was previously reported as a component of the allowance for credit losses on loans and leases to be netted directly against loans and leases held for investment on the Company’s consolidated balance sheet. Amounts reclassified from the allowance for credit losses on loans and leases to net directly against total loans and leases held for investment was $20.0 million, as of December 31, 2019. In addition, the change in the credit component of the fair value discount was previously reported in the provision for loan and lease credit losses while the change in the liquidity component of the fair value discount was previously reported in the loan servicing asset revaluation in the consolidated statements of income, but both have now been reclassified to net (loss) gain on loans accounted for under the fair value option. Amounts reclassified from the provision for loan and lease credit losses and the loan servicing asset revaluation to net (loss) gain on loans accounted for under the fair value option were $(289) thousand and $(1.8) million, respectively, for the quarter ended March 31, 2019. The effect of the above discussed reclassifications on the consolidated balance sheets, consolidated statements of income, and consolidated statements of cash flows for each period are presented below, with additional parenthetical disclosures added: As Reported Reclassifications As Reclassified Consolidated Balance Sheet as of December 31, 2019 Loans held for sale $ 966,447 $ — $ 966,447 Loans and leases held for investment 2,647,299 (20,013 ) 2,627,286 Allowance for credit losses on loans and leases (48,247 ) 20,013 (28,234 ) Net loans and leases 2,599,052 — 2,599,052 Total assets 4,814,970 — 4,814,970 Consolidated Statement of Income for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net interest income after provision for loan and lease credit losses 27,863 (289 ) 27,574 Loan servicing asset revaluation (2,246 ) (1,794 ) (4,040 ) Net (loss) gain on loans accounted for under the fair value option — 2,083 2,083 Total noninterest income 13,027 289 13,316 Net income 2,372 — 2,372 Consolidated Statement of Cash Flows for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net decrease in servicing assets 3,317 — 3,317 Change in discount on unguaranteed loans (1,319 ) 1,319 — Net loss (gain) on loans accounted for under fair value option — (2,083 ) (2,083 ) Net cash used by operating activities (107,313 ) (475 ) (107,788 ) Loan and lease originations and principal collections, net (113,539 ) 475 (113,064 ) Net cash used by investing activities (301,402 ) 475 (300,927 ) |
Adoption of New Accounting Standard | Adoption of New Accounting Standard On January 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”) along with its amendments, which replaces the incurred loss impairment methodology in current standards with the current expected credit loss methodology (“CECL”) and requires consideration of a broader range of information to determine credit loss estimates. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts and requires enhanced disclosures related to the significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell. The Company adopted Accounting Standards Codification (“ASC”) 326 using the modified retrospective method for all financial assets measured at amortized cost and off-balance-sheet credit exposures. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 while prior period amounts continue to be reported in accordance with previously applicable GAAP. The Company recorded a net increase to retained earnings of $822 thousand, comprised of a $1.3 million decrease in the allowance for credit losses combined with a $499 thousand increase in reserve on unfunded commitments, as of January 1, 2020 for the cumulative effect of adopting ASC 326. Allowance for Credit Losses – Loans and Leases Held for Investment The allowance for credit losses (“ACL”) is a valuation account that is deducted from, or added to, the amortized cost basis of loans and leases to present a net amount expected to be collected. The ACL excludes loans held for sale and loans accounted for under the fair value option. Loans and leases are charged-off against the ACL when management believes the uncollectibility of a loan or lease balance is confirmed. Expected recoveries do not exceed the aggregate of amounts previously charged-off and expected to be charged-off. The Company’s ACL on loans and leases is estimated using relevant information, from internal and external sources, relating to past events, current conditions, and reasonable and supportable forecasts. The Company’s historical credit loss experience provides the basis for the estimation of expected credit losses. Management adjusts historical loss information for differences in current risk characteristics such as portfolio risk grading, delinquency levels, or portfolio mix as well as for changes in environmental conditions such as changes in unemployment rates. The ACL is measured on a pooled basis when similar risk characteristics are present in the portfolio. The Company has identified portfolio segments based on industry and whether the receivable is secured by real estate or another form of collateral. Additional information related to the portfolio segments can be found in the Company’s 2019 Form 10-K. Expected credit losses for pooled loans and leases are estimated using a discounted cash flow (“DCF”) methodology. Loans or leases that do not share risk characteristics are evaluated on an individual basis and are excluded from the pooled evaluation. This generally occurs when, based on current information and events, it is probable that the Company will be unable to collect all interest and principal payments due according to the originally contracted, or reasonably modified, terms of the loan or lease agreement. The Company has determined that loans and leases meeting the criteria defined below must be reviewed quarterly to determine if they should be evaluated for expected credit losses on an individual basis. • All commercial loans and leases classified substandard or worse. • Any loan or lease that is on nonaccrual, or any loan or lease that is delinquent greater than 90 days past due and still accruing interest. • Any loan or lease that it meets the definition of a troubled debt restructuring (“TDR”). Expected credit losses are estimated over the contractual term of the loan or lease, adjusted for expected prepayments when appropriate. The contractual term excludes expected extensions, renewals, and modifications unless management has a reasonable expectation at the reporting date that a TDR will be executed with an individual borrower or the extension or renewal options are included in the contract at the reporting date and are not unconditionally cancellable by the Company. When the ACL, for pooled or individually evaluated loans and leases, is estimated using the DCF method, the effective interest rate used to discount expected cash flows is adjusted for expected prepayments. Past due status of loans and leases is determined based on contractual terms. Loans and leases are placed in nonaccrual status and interest accrual is discontinued if they become 90 days delinquent or there is evidence that the borrower’s ability to make the required payments is impaired. A loan or lease is accounted for as a TDR if the Company, for reasons related to the borrower’s financial difficulties, restructures a loan or lease, and grants a concession to the borrower that it would not otherwise grant. A TDR typically involves a more than short-term modification of terms such as a reduction of the interest rate below the current market rate for a loan or lease with similar risk characteristics or the waiving of certain financial covenants without corresponding offsetting compensation or additional support. When management determines that foreclosure is probable or when the borrower is experiencing financial difficulty at the reporting date and repayment is expected to be provided substantially through the operation or sale of the collateral, expected credit losses are based on the fair value of the collateral at the reporting date, adjusted for selling costs as appropriate. Allowance for Credit Losses – Off-Balance Sheet Credit Exposures Expected credit losses on off-balance sheet credit exposures is estimated over the contractual period in which the Company is exposed to such losses, unless the obligation to extend credit is unconditionally cancellable. The estimate of off-balance sheet credit exposures includes consideration of the likelihood that funding will occur and an estimate of expected credit losses on commitments expected to be funded over its estimated losses. The estimate is influenced by historical loss experience, adjusted for current risk characteristics, and economic forecasts. Allowance for Credit Losses – Available-for-Sale Securities When available-for-sale debt securities are in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. Available-for-sale debt securities that do not meet the aforementioned criteria are evaluated to determine whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected from the security is less than the amortized cost basis, a credit loss exists and an ACL is recorded for the credit loss, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. Changes in the ACL are recorded as provision for (or reversal of) credit loss expense. Losses are charged against the allowance when management believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. Management has made the accounting policy election to exclude accrued interest receivable on available-for-sale debt securities from the estimate of credit losses. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through income when deemed uncollectible by management or when either of the aforementioned criteria regarding intent or requirement to sell is met. |
Common Stock | |
Equity | Common Stock On March 15, 2020, the Board of Directors of the Company authorized the repurchase of up to $20,000,000 in shares of the Company’s voting common stock from time to time through December 31, 2020 (the “Repurchase Program”). The Repurchase Program enables the Company to acquire shares through open market purchases or privately negotiated transactions, including through a Rule 10b5-1 plan, at the discretion of management and on terms (including quantity, timing, and price) that management determines to be advisable. Actions in connection with the repurchase program will be subject to various factors, including the Company’s capital and liquidity positions, regulatory and accounting considerations, the Company’s financial and operational performance, alternative uses of capital, the trading price of the Company’s common stock, and market conditions. The repurchase program does not obligate the Company to acquire a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time. There were no shares repurchased during the three months ended March 31, 2020 |
Basis of Presentation (Tables)
Basis of Presentation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Effect of Reclassifications on Consolidated Balance Sheets, Consolidated Statements of Income, and Consolidated Statements of Cash Flows | The effect of the above discussed reclassifications on the consolidated balance sheets, consolidated statements of income, and consolidated statements of cash flows for each period are presented below, with additional parenthetical disclosures added: As Reported Reclassifications As Reclassified Consolidated Balance Sheet as of December 31, 2019 Loans held for sale $ 966,447 $ — $ 966,447 Loans and leases held for investment 2,647,299 (20,013 ) 2,627,286 Allowance for credit losses on loans and leases (48,247 ) 20,013 (28,234 ) Net loans and leases 2,599,052 — 2,599,052 Total assets 4,814,970 — 4,814,970 Consolidated Statement of Income for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net interest income after provision for loan and lease credit losses 27,863 (289 ) 27,574 Loan servicing asset revaluation (2,246 ) (1,794 ) (4,040 ) Net (loss) gain on loans accounted for under the fair value option — 2,083 2,083 Total noninterest income 13,027 289 13,316 Net income 2,372 — 2,372 Consolidated Statement of Cash Flows for the three months ended March 31, 2019 Provision for loan and lease credit losses $ 2,742 $ 289 $ 3,031 Net decrease in servicing assets 3,317 — 3,317 Change in discount on unguaranteed loans (1,319 ) 1,319 — Net loss (gain) on loans accounted for under fair value option — (2,083 ) (2,083 ) Net cash used by operating activities (107,313 ) (475 ) (107,788 ) Loan and lease originations and principal collections, net (113,539 ) 475 (113,064 ) Net cash used by investing activities (301,402 ) 475 (300,927 ) |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Earnings Per Share | Basic and diluted earnings per share are computed based on the weighted average number of shares outstanding during each period. Diluted earnings per share reflects the potential dilution that could occur, upon the exercise of stock options or upon the vesting of restricted stock grants, any of which would result in the issuance of common stock that would then be shared in the net income of the Company. Three Months Ended March 31, 2020 2019 Basic (loss) earnings per share: Net (loss attributable to) income available to common shareholders $ (7,602 ) $ 2,372 Weighted-average basic shares outstanding 40,334,179 40,160,118 Basic (loss) earnings per share $ (0.19 ) $ 0.06 Diluted (loss) earnings per share: Net (loss attributable to) income available to common shareholders, for diluted (loss) earnings per share $ (7,602 ) $ 2,372 Total weighted-average basic shares outstanding 40,334,179 40,160,118 Add effect of dilutive stock options and restricted stock grants 739,870 761,705 Total weighted-average diluted shares outstanding 41,074,049 40,921,823 Diluted (loss) earnings per share $ (0.19 ) $ 0.06 Anti-dilutive shares 1,839,601 1,597,589 |
Investment Securities (Tables)
Investment Securities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Summary of Carrying Amount and Fair Value of Securities | The carrying amount of investment securities and their approximate fair values are reflected in the following table: March 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Allowance for Credit Losses Fair Value US treasury securities $ 4,992 $ 51 $ — $ — $ 5,043 US government agencies 22,444 635 — — 23,079 Mortgage-backed securities 514,899 22,950 558 — 537,291 Municipal bonds 8,479 283 7 — 8,755 Total $ 550,814 $ 23,919 $ 565 $ — $ 574,168 December 31, 2019 US treasury securities $ 4,988 $ 27 $ — $ — $ 5,015 US government agencies 22,444 335 — — 22,779 Mortgage-backed securities 488,694 15,530 927 — 503,297 Municipal bonds 8,493 469 8 — 8,954 Total $ 524,619 $ 16,361 $ 935 $ — $ 540,045 |
Debt Securities Available-for-Sale in Unrealized Loss Position | The following tables show debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position. Less Than 12 Months 12 Months or More Total March 31, 2020 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Mortgage-backed securities $ 36,320 $ 213 $ 25,032 $ 345 $ 61,352 $ 558 Municipal bonds — — 93 7 93 7 Total $ 36,320 $ 213 $ 25,125 $ 352 $ 61,445 $ 565 Less Than 12 Months 12 Months or More Total December 31, 2019 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Mortgage-backed securities $ 42,835 $ 460 $ 36,518 $ 467 $ 79,353 $ 927 Municipal bonds — — 92 8 92 8 Total $ 42,835 $ 460 $ 36,610 $ 475 $ 79,445 $ 935 |
Summary of Investment Securities by Maturity | The following is a summary of investment securities by maturity: March 31, 2020 Amortized cost Fair value US treasury securities Within one year $ 4,992 $ 5,043 Total 4,992 5,043 US government agencies Within one year 7,007 7,070 One to five years 12,518 12,901 Five to ten years 2,919 3,108 Total 22,444 23,079 Mortgage-backed securities One to five years 4,700 4,853 Five to ten years 178,652 191,718 After 10 years 331,547 340,720 Total 514,899 537,291 Municipal bonds After 10 years 8,479 8,755 Total 8,479 8,755 Total $ 550,814 $ 574,168 |
Loans and Leases Held for Inv_2
Loans and Leases Held for Investment and Credit Quality (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Receivables [Abstract] | |
Summary of Total Loans and Leases and Aging Analysis of Portfolio Segments | The following tables present total loans and leases and an aging analysis for the Company’s portfolio segments. Loans and leases are considered past due if the required principal and interest payments have not been received as of the date such payments were due. Current or Less than 30 Days Past Due 30-89 Days Past Due 90 Days or More Past Due Total Past Due Total Carried at Amortized Cost 1 Loans Accounted for Under the Fair Value Option 2 Total Loans and Leases March 31, 2020 Commercial & Industrial Agriculture $ 10,370 $ 1 $ — $ 1 $ 10,371 $ 361 $ 10,732 Funeral Home & Cemetery 15,092 — — — 15,092 12,036 27,128 Healthcare 26,877 1,719 1,322 3,041 29,918 19,826 49,744 Independent Pharmacies 25,320 — — — 25,320 78,540 103,860 Registered Investment Advisors 40,269 — — — 40,269 58,016 98,285 Veterinary Industry 31,336 481 — 481 31,817 20,643 52,460 Other Industries 442,930 10,271 5,637 15,908 458,838 172,072 630,910 Total 592,194 12,472 6,959 19,431 611,625 361,494 973,119 Construction & Development Agriculture 45,333 — — — 45,333 — 45,333 Funeral Home & Cemetery 9,146 — — — 9,146 — 9,146 Healthcare 97,404 3,387 — 3,387 100,791 — 100,791 Independent Pharmacies 720 — — — 720 — 720 Registered Investment Advisors 2,564 — — — 2,564 — 2,564 Veterinary Industry 20,862 — — — 20,862 — 20,862 Other Industries 193,181 — — — 193,181 — 193,181 Total 369,210 3,387 — 3,387 372,597 — 372,597 Commercial Real Estate Agriculture 1,291 — — — 1,291 762 2,053 Funeral Home & Cemetery 58,699 — — — 58,699 58,611 117,310 Healthcare 140,375 — 4,498 4,498 144,873 107,437 252,310 Independent Pharmacies 8,609 — 822 822 9,431 17,182 26,613 Registered Investment Advisors 2,635 — — — 2,635 4,591 7,226 Veterinary Industry 68,831 2,953 1,089 4,042 72,873 71,129 144,002 Other Industries 427,669 6,326 1,849 8,175 435,844 92,105 527,949 Total 708,109 9,279 8,258 17,537 725,646 351,817 1,077,463 Commercial Land Agriculture 268,096 — 2,170 2,170 270,266 118,115 388,381 Total 268,096 — 2,170 2,170 270,266 118,115 388,381 Total $ 1,937,609 $ 25,138 $ 17,387 $ 42,525 $ 1,980,134 $ 831,426 $ 2,811,560 Net Deferred Costs $ 5,931 Loan and Leases, Net of unearned $ 2,817,491 Current or Less than 30 Days Past Due 30-89 Days Past Due 90 Days or More Past Due Total Past Due Total Carried at Amortized Cost 1 Loans Accounted for Under the Fair Value Option 2 Total Loans and Leases December 31, 2019 Commercial & Industrial Agriculture $ 8,941 $ — $ — $ — $ 8,941 $ 396 $ 9,337 Funeral Home & Cemetery 14,086 — — — 14,086 12,343 26,429 Healthcare 21,746 812 1,497 2,309 24,055 20,999 45,054 Independent Pharmacies 25,348 — — — 25,348 79,787 105,135 Registered Investment Advisors 42,421 — — — 42,421 56,769 99,190 Veterinary Industry 28,728 504 — 504 29,232 21,799 51,031 Other Industries 399,723 6,579 3,856 10,435 410,158 141,220 551,378 Total 540,993 7,895 5,353 13,248 554,241 333,313 887,554 Construction & Development Agriculture 44,571 — — — 44,571 — 44,571 Funeral Home & Cemetery 9,033 — — — 9,033 — 9,033 Healthcare 94,742 — — — 94,742 — 94,742 Independent Pharmacies 443 — — — 443 — 443 Registered Investment Advisors 2,404 — — — 2,404 — 2,404 Veterinary Industry 22,132 — — — 22,132 — 22,132 Other Industries 173,993 — — — 173,993 — 173,993 Total 347,318 — — — 347,318 — 347,318 Commercial Real Estate Agriculture 30,066 — — — 30,066 19,975 50,041 Funeral Home & Cemetery 53,426 1,817 — 1,817 55,243 58,171 113,414 Healthcare 125,622 — 4,498 4,498 130,120 115,887 246,007 Independent Pharmacies 8,070 930 — 930 9,000 17,013 26,013 Registered Investment Advisors 2,543 — — — 2,543 4,913 7,456 Veterinary Industry 65,928 1,727 1,088 2,815 68,743 76,154 144,897 Other Industries 361,394 4,585 — 4,585 365,979 93,537 459,516 Total 647,049 9,059 5,586 14,645 661,694 385,650 1,047,344 Commercial Land Agriculture 234,133 — — — 234,133 105,557 339,690 Total 234,133 — — — 234,133 105,557 339,690 Total $ 1,769,493 $ 16,954 $ 10,939 $ 27,893 $ 1,797,386 $ 824,520 $ 2,621,906 Net Deferred Costs $ 5,380 Loan and Leases, Net of unearned $ 2,627,286 1 Total loans and leases include $665.1 million of U.S. government guaranteed loans as of March 31, 2020, of which $12.0 million is greater than 90 days or more past due, $19.4 million is past due 30-89 days and $633.7 million are current. Total loans and leases include $622.6 million of U.S. government guaranteed loans as of December 31, 2019, of which $6.4 million is greater than 90 days or more past due, $13.6 million is past due 30-89 days and $602.6 million are current. 2 The Company measures the carrying value of the retained portion of loans sold at fair value under ASC Subtopic 825-10. See Note 9. Fair Value of Financial Instruments for additional information. |
Summary of Asset Quality Indicators by Portfolio Segment and Origination Year | The following tables presents asset quality indicators by portfolio segment and origination year. See Note 5. Loans and Leases Held for Investment and Credit Quality in the Company’s 2019 Form 10-K for additional discussion around the asset quality indicators that the Company uses to manage and monitor credit risk. Term Loans and Leases Amortized Cost Basis by Origination Year 2020 2019 2018 2017 2016 Prior Revolving Loans Amortized Cost Basis Revolving Loans Converted to Term Total 1,2 March 31, 2020 Commercial & Industrial Risk Grades 1 - 4 $ 71,188 $ 260,917 $ 68,136 $ 44,091 $ 12,455 $ 5,108 $ 99,612 $ 627 $ 562,134 Risk Grade 5 — 6,770 14,554 31 — 313 8,201 79 29,948 Risk Grades 6 - 8 — 3,300 10,968 3,852 — 481 942 — 19,543 Total 71,188 270,987 93,658 47,974 12,455 5,902 108,755 706 611,625 Construction & Development Risk Grades 1 - 4 18,172 141,380 138,387 43,656 11,128 449 2,175 — 355,347 Risk Grade 5 — — 7,788 8,758 — — — — 16,546 Risk Grades 6 - 8 — — — 704 — — — — 704 Total 18,172 141,380 146,175 53,118 11,128 449 2,175 — 372,597 Commercial Real Estate Risk Grades 1 - 4 56,428 160,097 119,640 178,714 84,876 51,762 1,817 172 653,506 Risk Grade 5 — — 14,256 7,767 22,351 5,098 200 — 49,672 Risk Grades 6 - 8 — — — 8,246 9,822 4,400 — — 22,468 Total 56,428 160,097 133,896 194,727 117,049 61,260 2,017 172 725,646 Commercial Land Risk Grades 1 - 4 5,626 31,404 54,474 55,682 66,166 52,576 — — 265,928 Risk Grade 5 — — — — — — — — — Risk Grades 6 - 8 — — 4 — — 4,334 — — 4,338 Total 5,626 31,404 54,478 55,682 66,166 56,910 — — 270,266 Total $ 151,414 $ 603,868 $ 428,207 $ 351,501 $ 206,798 $ 124,521 $ 112,947 $ 878 $ 1,980,134 Total 1,2 December 31, 2019 Commercial & Industrial Risk Grades 1 - 4 $ 510,508 Risk Grade 5 32,462 Risk Grades 6 - 8 11,271 Total 554,241 Construction & Development Risk Grades 1 - 4 331,135 Risk Grade 5 15,477 Risk Grades 6 - 8 706 Total 347,318 Commercial Real Estate Risk Grades 1 - 4 599,298 Risk Grade 5 41,573 Risk Grades 6 - 8 20,823 Total 661,694 Commercial Land Risk Grades 1 - 4 227,377 Risk Grade 5 — Risk Grades 6 - 8 6,756 Total 234,133 Total $ 1,797,386 1 Total loans and leases include $665.1 million of U.S. government guaranteed loans as of March 31, 2020, segregated by risk grade as follows: Risk Grades 1 – 4 = $584.5 million, Risk Grade 5 = $50.0 million, Risk Grades 6 – 8 = $30.6 million. As of December 31, 2019, total loans and leases include $622.6 million of U.S. government guaranteed loans, segregated by risk grade as follows: Risk Grades 1 – 4 = $556.8 million, Risk Grade 5 = $42.7 million, Risk Grades 6 – 8 = $23.1 million. Total loans and leases exclude loans accounted for under the fair value option. 2 Excludes $831.4 million and $824.5 million of loans accounted for under the fair value option as of March 31, 2020 and December 31, 2019, respectively. |
Nonaccrual Loans and Leases | Nonaccrual loans and leases as of March 31, 2020 and December 31, 2019 are as follows: March 31, 2020 Loan Balance 1 Guaranteed Balance Unguaranteed Balance Unguaranteed Exposure with No ACL Commercial & Industrial Agriculture $ 1 $ 1 $ — $ — Healthcare 2,099 1,905 194 — Independent Pharmacies 4,424 3,318 1,106 — Veterinary Industry 481 481 — — Other Industries 9,217 7,181 2,036 — Total 16,222 12,886 3,336 — Commercial Real Estate Healthcare 4,498 1,254 3,244 1,841 Independent Pharmacies 822 698 124 — Veterinary Industry 2,770 2,143 627 — Other Industries 5,439 4,079 1,360 — Total 13,529 8,174 5,355 1,841 Commercial Land Agriculture 4,337 3,405 932 32 Total 4,337 3,405 932 32 Total $ 34,088 $ 24,465 $ 9,623 $ 1,873 December 31, 2019 Loan Balance 1 Guaranteed Balance Unguaranteed Balance Commercial & Industrial Agriculture $ 269 $ 215 $ 54 Healthcare 2,309 1,931 378 Veterinary Industry 504 504 — Other Industries 3,856 2,906 950 Total 6,938 5,556 1,382 Commercial Real Estate Healthcare 4,498 1,254 3,244 Independent Pharmacies 931 698 233 Veterinary Industry 2,816 2,178 638 Total 8,245 4,130 4,115 Commercial Land Agriculture 6,756 5,028 1,728 Total 6,756 5,028 1,728 Total $ 21,939 $ 14,714 $ 7,225 1 Excludes nonaccrual loans accounted for under the fair value option. See Note 9. Fair Value of Financial Instruments for additional information. |
Amortized Cost Basis of Collateral-Dependent Loans and Leases | The following table presents the amortized cost basis of collateral-dependent loans and leases, which are individually evaluated to determine expected credit losses, as of March 31, 2020: Total Collateral Dependent Loans Unguaranteed Portion March 31, 2020 Real Estate Business Assets Other Real Estate Business Assets Other Allowance for Credit Losses Commercial & Industrial Healthcare $ 1,188 $ 178 $ — $ 41 $ 3 $ — $ 44 Independent Pharmacies — 4,514 — — 1,196 — 1,177 Other Industries 4,586 2,267 2,148 1,363 557 148 1,067 Total 5,774 6,959 2,148 1,404 1,756 148 2,288 Commercial Real Estate Healthcare 1,821 — — 1,821 — — — Independent Pharmacies 826 — — 128 — — 4 Veterinary Industry 2,792 — — 649 — — 180 Other Industries 5,449 — — 1,371 — — 3 Total 10,888 — — 3,969 — — 187 Commercial Land Agriculture 4,359 — — 952 — — 328 Total 4,359 — — 952 — — 328 Total $ 21,021 $ 6,959 $ 2,148 $ 6,325 $ 1,756 $ 148 $ 2,803 |
Activity in ACL and Allowance for Loan and Lease Losses by Portfolio Segment | The following table details activity in the ACL by portfolio segment allowance for the periods presented: Three Months Ended Construction & Development Commercial Real Estate Commercial & Industrial Commercial Land Total March 31, 2020 Beginning Balance, prior to adoption of ASC 326 $ 2,732 $ 8,427 $ 15,757 $ 1,318 $ 28,234 Impact of adopting ASC 326 1,131 1,916 (4,561 ) 193 (1,321 ) Charge offs — (109 ) (2,345 ) (408 ) (2,862 ) Recoveries — 28 35 — 63 Provision 960 2,848 7,451 533 11,792 Ending Balance $ 4,823 $ 13,110 $ 16,337 $ 1,636 $ 35,906 March 31, 2019 Beginning Balance $ 2,042 $ 5,259 $ 6,524 $ 607 $ 14,432 Charge offs — — — — — Recoveries — 8 79 — 87 Provision 194 112 1,679 1,046 3,031 Ending Balance $ 2,236 $ 5,379 $ 8,282 $ 1,653 $ 17,550 The following tables detail the recorded allowance for loan and lease losses and the investment in loans and leases related to each portfolio segment, disaggregated on the basis of impairment evaluation methodology: December 31, 2019 Construction & Development Commercial Real Estate Commercial & Industrial Commercial Land Total 1,2 Allowance for loan and lease losses: Loans and leases individually evaluated for impairment $ 17 $ 2,067 $ 3,989 $ 748 $ 6,821 Loans and leases collectively evaluated for impairment 2,715 6,360 11,768 570 21,413 Total allowance for loan and lease losses $ 2,732 $ 8,427 $ 15,757 $ 1,318 $ 28,234 Loans and leases receivable: Loans and leases individually evaluated for impairment $ 719 $ 25,389 $ 14,052 $ 17,347 $ 57,507 Loans and leases collectively evaluated for impairment 346,599 636,305 540,189 216,786 1,739,879 Total loans and leases receivable $ 347,318 $ 661,694 $ 554,241 $ 234,133 $ 1,797,386 1 As of December 31, 2019, loans and leases receivable includes $622.6 million of U.S. government guaranteed loans, of which $36.0 million are considered impaired. 2 Loans and leases receivable exclude $824.5 million of loans accounted for under the fair value option. |
Troubled Debt Restructurings on Financing Receivables | The following tables represent the types of TDRs that were made during the periods presented: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 All Restructurings All Restructurings Number of Loans Recorded investment at period end Number of Loans Recorded investment at period end Extended Amortization Commercial Land Agriculture — $ — 1 $ 3,489 Commercial & Industrial Other Industries 1 973 — — Total Extend Amortization 1 973 1 3,489 Payment Deferral Commercial & Industrial Other Industries 2 1,487 — — Commercial Real Estate Healthcare — — 1 1,853 Other Industries 1 3,589 — — Total Payment Deferral 3 5,076 1 1,853 Total 4 $ 6,049 2 $ 5,342 |
Impaired Loans and Leases | Loans and leases classified as impaired as of the dates presented are summarized in the following tables. December 31, 2019 Recorded Investment Guaranteed Balance Unguaranteed Exposure Commercial & Industrial Agriculture $ 367 $ 215 $ 152 Healthcare 3,760 1,931 1,829 Veterinary Industry 504 504 — Other Industries 9,421 5,348 4,073 Total 14,052 7,998 6,054 Construction & Development Healthcare 719 530 189 Total 719 530 189 Commercial Real Estate Healthcare 12,677 5,101 7,576 Independent Pharmacies 933 698 235 Veterinary Industry 5,907 4,707 1,200 Other Industries 5,872 4,079 1,793 Total 25,389 14,585 10,804 Commercial Land Agriculture 17,347 12,898 4,449 Total 17,347 12,898 4,449 Total $ 57,507 $ 36,011 $ 21,496 The following table presents evaluated balances of loans and leases classified as impaired at the dates presented that carried an associated reserve as compared to those with no reserve. The recorded investment includes accrued interest and net deferred loan and lease fees or costs. December 31, 2019 Recorded Investment With a Recorded Allowance With No Recorded Allowance Total Unpaid Principal Balance Related Allowance Recorded Commercial & Industrial Agriculture $ 362 $ 5 $ 367 $ 378 $ 95 Healthcare 3,760 — 3,760 4,109 975 Veterinary Industry 504 — 504 672 4 Other Industries 9,421 — 9,421 9,725 2,915 Total 14,047 5 14,052 14,884 3,989 Construction & Development Healthcare 719 — 719 706 17 Total 719 — 719 706 17 Commercial Real Estate Healthcare 10,835 1,842 12,677 12,602 1,579 Independent Pharmacies 933 — 933 930 88 Veterinary Industry 5,907 — 5,907 6,615 311 Other Industries 5,611 261 5,872 5,697 89 Total 23,286 2,103 25,389 25,844 2,067 Commercial Land Agriculture 17,347 — 17,347 17,399 748 Total 17,347 — 17,347 17,399 748 Total Impaired Loans and Leases $ 55,399 $ 2,108 $ 57,507 $ 58,833 $ 6,821 The following table presents the average recorded investment of impaired loans and leases for each period presented and interest income recognized during the period in which the loans and leases were considered impaired. Three Months Ended March 31, 2019 Average Balance Interest Income Recognized Commercial & Industrial Agriculture $ 6 $ — Healthcare 4,492 29 Veterinary Industry 632 1 Other Industries 3,532 17 Total 8,662 47 Commercial Real Estate Healthcare 9,772 101 Veterinary Industry 6,282 41 Other Industries 1,588 — Total 17,642 142 Commercial Land Agriculture 21,505 196 Total 21,505 196 Total $ 47,809 $ 385 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Net Lease Investment | The gross lease payments receivable and the net investment included in accounts receivable for such leases are as follows: March 31, 2020 December 31, 2019 Gross direct finance lease payments receivable $ 13,197 $ 13,959 Less – unearned interest (2,334 ) (2,562 ) Net investment in direct financing leases $ 10,863 $ 11,397 |
Future Minimum Capital Lease Payments | Future minimum lease payments under finance leases are as follows: As of March 31, 2020 Amount 2020 $ 2,367 2021 2,928 2022 2,699 2023 2,259 2024 1,635 Thereafter 1,309 Total $ 13,197 |
Maturity Analysis of Future Minimum Operating Lease Payments | A maturity analysis of future minimum lease payments under non-cancelable operating leases is as follows: As of March 31, 2020 Amount 2020 $ 7,060 2021 9,052 2022 9,044 2023 9,075 2024 8,808 Thereafter 40,110 Total $ 83,149 |
Servicing Assets (Tables)
Servicing Assets (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Transfers And Servicing [Abstract] | |
Summary of Activity Pertaining to Servicing Rights | The following summarizes the activity pertaining to servicing rights: Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 35,365 $ 47,641 Additions, net 2,859 723 Fair value changes: Due to changes in valuation inputs or assumptions (2,039 ) (524 ) Decay due to increases in principal paydowns or runoff (2,653 ) (3,516 ) Balance at end of period $ 33,532 $ 44,324 |
Borrowings (Tables)
Borrowings (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Total Outstanding Borrowings | Total outstanding borrowings consisted of the following: March 31, 2020 December 31, 2019 Borrowings In 2019, the Company renewed a revolving line of credit issued in 2017. The line of credit is unsecured and accrues interest at 30-day LIBOR plus 1.15% for a term of 13 months. Payments are interest only with all principal and accrued interest due on October 20, 2020. The terms of this loan require the Company to maintain minimum capital and debt service coverage ratios. This $50 million line of credit has been fully advanced and there is no available credit remaining at March 31, 2020. $ 50,000 $ — In October 2017, the Company entered into a financing lease of $19 thousand with an unaffiliated equipment lease company, secured by fitness equipment which is included in other assets on the consolidated balance sheet. Payments are principal and interest due monthly starting December 15, 2017 over a term of 60 months. At the end of the lease term there is a $1.00 bargain purchase option. As of January 1, 2019, this borrowing was revised in accordance with ASU 2016-02. 12 14 Total borrowings $ 50,012 $ 14 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Record Amount of Assets and Liabilities Measured at Fair Value on a Recurring Basis | The tables below present the recorded amount of assets and liabilities measured at fair value on a recurring basis. March 31, 2020 Total Level 1 Level 2 Level 3 Investment securities available-for-sale US treasury securities $ 5,043 $ — $ 5,043 $ — US government agencies 23,079 — 23,079 — Mortgage-backed securities 537,291 — 537,291 — Municipal bonds 1 8,755 — 8,662 93 Loans held for sale 19,151 — — 19,151 Loans held for investment 831,426 — — 831,426 Servicing assets 2 33,532 — — 33,532 Mutual fund 2,141 — 2,141 — Equity warrant assets 3 702 — — 702 Total assets at fair value $ 1,461,120 $ — $ 576,216 $ 884,904 December 31, 2019 Total Level 1 Level 2 Level 3 Investment securities available-for-sale US treasury securities $ 5,015 $ — $ 5,015 $ — US government agencies 22,779 — 22,779 — Mortgage-backed securities 503,297 — 503,297 — Municipal bonds 1 8,954 — 8,862 92 Loans held for sale 16,198 — — 16,198 Loans held for investment 824,520 — — 824,520 Servicing assets 2 35,365 — — 35,365 Mutual fund 2,206 — 2,206 — Equity warrant assets 3 570 — — 570 Total assets at fair value $ 1,418,904 $ — $ 542,159 $ 876,745 1 During the three months ended March 31, 2020, the Company recorded a fair value adjustment gain of $1 thousand. During the three months ended March 31, 2019, the Company sold $900 thousand of a municipal bond to a third party and recorded a fair value adjustment loss of $9 thousand. 2 See Note 7 for a rollforward of recurring Level 3 fair values for servicing assets. 3 During the three months ended March 31, 2020, the Company entered into equity warrant assets with a fair value of $164 thousand at the time of issuance and recorded net losses on derivative instruments of $32 thousand. During the three months ended March 31, 2019, the Company recorded net gains on derivative instruments of $255 thousand. |
Summary of Fair Value Carrying Amount and Unpaid Principal Outstanding of Loans Under Fair Value Option | The following tables provide more information about the fair value carrying amount and the unpaid principal outstanding of loans accounted for under the fair value option at March 31, 2020 and December 31, 2019. March 31, 2020 Total Loans Nonaccruals 90 Days or More Past Due Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Option Elections Loans held for sale $ 19,151 $ 20,056 $ (905 ) $ — $ — $ — $ — $ — $ — Loans held for investment 831,426 858,577 (27,151 ) 60,558 65,303 (4,745 ) 39,102 40,876 (1,774 ) $ 850,577 $ 878,633 $ (28,056 ) $ 60,558 $ 65,303 $ (4,745 ) $ 39,102 $ 40,876 $ (1,774 ) December 31, 2019 Total Loans Nonaccruals 90 Days or More Past Due Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Carrying Amount Unpaid Principal Balance Difference Fair Value Option Elections Loans held for sale $ 16,198 $ 17,230 $ (1,032 ) $ — $ — $ — $ — $ — $ — Loans held for investment 824,520 842,456 (17,936 ) 49,739 54,370 (4,631 ) 26,644 28,137 (1,493 ) $ 840,718 $ 859,686 $ (18,968 ) $ 49,739 $ 54,370 $ (4,631 ) $ 26,644 $ 28,137 $ (1,493 ) |
Schedule of Net Gains (Losses) from Changes in Fair Value | The following table presents the net gains (losses) from changes in fair value. Three Months Ended March 31, Gains (Losses) on Loans Accounted for under the Fair Value Option 2020 2019 Loans held for sale $ 120 $ (351 ) Loans held for investment (10,758 ) 2,434 $ (10,638 ) $ 2,083 |
Summary of the Activity Pertaining to Loans Accounted for Under Fair Value Option | The following tables summarize the activity pertaining to loans accounted for under the fair value option. Three Months Ended March 31, Loans held for sale 2020 2019 Balance at beginning of period $ 16,198 $ 17,745 Issuances 3,045 13,635 Fair value changes 120 (351 ) Sales — (5,700 ) Settlements (212 ) (36 ) Balance at end of period $ 19,151 $ 25,293 Three Months Ended March 31, Loans held for investment 2020 2019 Balance at beginning of period $ 824,520 $ 885,527 Issuances 61,611 30,108 Fair value changes (10,758 ) 2,434 Settlements (43,947 ) (49,415 ) Balance at end of period $ 831,426 $ 868,654 |
Recorded Amount of Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis | The tables below present the recorded amount of assets and liabilities measured at fair value on a non-recurring basis. March 31, 2020 Total Level 1 Level 2 Level 3 Collateral dependent loans $ 2,349 $ — $ — $ 2,349 Foreclosed assets 6,744 — — 6,744 Total assets at fair value $ 9,093 $ — $ — $ 9,093 December 31, 2019 Total Level 1 Level 2 Level 3 Collateral dependent loans $ 1,245 $ — $ — $ 1,245 Foreclosed assets 5,612 — — 5,612 Equity security investment with a non-readily determinable fair value 8,738 8,738 — — Total assets at fair value $ 15,595 $ 8,738 $ — $ 6,857 |
Analysis of Level 3 Valuation Techniques | For Level 3 assets and liabilities measured at fair value on a recurring or non-recurring basis as of March 31, 2020 and December 31, 2019 the significant unobservable inputs used in the fair value measurements were as follows: March 31, 2020 Level 3 Assets with Significant Unobservable Inputs Fair Value Valuation Technique Significant Unobservable Inputs Range Recurring fair value Municipal bond $ 93 Discounted expected cash flows Discount rate Prepayment speed 4.2% 5.0% Loans held for sale $ 19,151 Discounted expected cash flows Discount rate Prepayment speed 7.1% to 15.4% WAVG 17.9% Loans held for investment $ 831,426 Discounted expected cash flows Discounted appraisals Loss rate Discount rate Prepayment speed Appraisal adjustments 0.0% to 82.5% (WAVG 1.8%) 7.1% to 15.4% WAVG 17.9% 10% to 50% Equity warrant assets $ 702 Black-Scholes option pricing model Volatility Risk-free interest rate Marketability discount Remaining life 24.7 to 85.4% 0.7% 20.0% 7-10 years Non-recurring fair value Collateral dependent loans $ 2,349 Discounted appraisals Appraisal adjustments (1) 10.0% to 55.0% Foreclosed assets $ 6,744 Discounted appraisals Appraisal adjustments (1) 4.0% to 14.5% December 31, 2019 Level 3 Assets with Significant Unobservable Inputs Fair Value Valuation Technique Significant Unobservable Inputs Range Recurring fair value Municipal bond $ 92 Discounted expected cash flows Discount rate Prepayment speed 4.6% 5.0% Loans held for sale $ 16,198 Discounted expected cash flows Discount rate Prepayment speed 7.7% to 21.4% WAVG 13.1% Loans held for investment $ 824,520 Discounted expected cash flows Discounted appraisals Loss rate Discount rate Prepayment speed Appraisal adjustments 0.0% to 10.9% (WAVG 1.3%) 7.7% to 21.4% WAVG 13.1% 10.0% to 70.0% Equity warrant assets $ 570 Black-Scholes option pricing model Volatility Risk-free interest rate Marketability discount Remaining life 21.0-75.0% 1.90% 20.0% 8-10 years Non-recurring fair value Collateral dependent loans $ 1,245 Discounted appraisals Appraisal adjustments (1) 10.0% to 57.0% Foreclosed assets $ 5,612 Discounted appraisals Appraisal adjustments (1) 10.0% to 37.0% (1) Appraisals may be adjusted by management for customized discounting criteria, estimated sales costs, and proprietary qualitative adjustments. |
Carrying Amount and Estimated Fair Value of Financial Instruments | The carrying amounts and estimated fair values of the Company’s financial instruments not measured at fair value on a recurring or non-recurring basis are as follows: March 31, 2020 Carrying Amount Quoted Price In Active Markets for Identical Assets /Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Financial assets Cash and due from banks $ 256,824 $ 256,824 $ — $ — $ 256,824 Federal funds sold 158,226 158,226 — — 158,226 Certificates of deposit with other banks 7,250 7,755 — — 7,755 Loans held for sale 976,899 — — 1,044,207 1,044,207 Loans and leases, net of allowance for credit losses on loans and leases 1,950,159 — — 2,053,965 2,053,965 Financial liabilities Deposits 4,642,148 — 4,717,676 — 4,717,676 Borrowings 50,012 — — 50,301 50,301 December 31, 2019 Carrying Amount Quoted Price In Active Markets for Identical Assets /Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Financial assets Cash and due from banks $ 126,752 $ 126,752 $ — $ — $ 126,752 Federal funds sold 96,787 96,787 — — 96,787 Certificates of deposit with other banks 7,250 7,568 — — 7,568 Loans held for sale 950,249 — — 1,004,135 1,004,135 Loans and leases, net of allowance for credit losses on loans and leases 1,774,532 — — 1,822,569 1,822,569 Financial liabilities Deposits 4,229,122 — 4,213,657 — 4,213,657 Borrowings 14 — — 14 14 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Summary of Commitments | A summary of the Company’s commitments is as follows: March 31, 2020 December 31, 2019 Commitments to extend credit $ 1,732,944 $ 1,834,449 Standby letters of credit 27,512 25,532 Operating lease commitments 803 — Total unfunded off-balance-sheet credit risk $ 1,761,259 $ 1,859,981 |
Significant Equity Method Inv_2
Significant Equity Method Investments (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Equity Method Investments And Joint Ventures [Abstract] | |
Summary of Balance Sheet and Income Statement Information of Equity Method Investments | The following table provides summarized balance sheet information for the Company’s equity method investments as of March 31, 2020 and December 31, 2019. The Company’s equity method investments are included in the other assets line on the consolidated balances sheet and are largely concentrated in new or emerging financial service technology companies. March 31, 2020 December 31, 2019 Balance sheet data Current assets $ 52,228 $ 56,710 Noncurrent assets 176,472 162,304 Total assets $ 228,700 $ 219,014 Current liabilities $ 20,183 $ 19,910 Noncurrent liabilities 664 683 Total liabilities 20,847 20,593 Equity interests 207,853 198,421 Total liabilities and equity $ 228,700 $ 219,014 The following table provides summarized income statement information for the Company’s equity method investments for the three months ended March 31, 2020 and 2019. Three Months Ended March 31, 2020 2019 Summary of operations Total revenues $ 15,792 $ 13,389 Net loss (16,433 ) (7,120 ) |
Basis of Presentation - Narrati
Basis of Presentation - Narrative (Details) - USD ($) | Jan. 01, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Mar. 15, 2020 | Dec. 31, 2019 |
Schedule Of Equity Method Investments [Line Items] | |||||
Loans and leases held for investment | $ (2,817,491,000) | $ (2,627,286,000) | |||
Loan servicing asset revaluation | (4,692,000) | $ (4,040,000) | |||
Retained earnings | $ 172,276,000 | 180,265,000 | |||
Repurchase Program | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Shares authorized to be repurchased | $ 20,000,000 | ||||
Shares repurchased during the period | 0 | ||||
Restatement Adjustment | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Loans and leases held for investment | $ 20,013,000 | ||||
Provision for loan and lease credit losses | (289,000) | ||||
Loan servicing asset revaluation | $ (1,794,000) | ||||
Restatement Adjustment | Accounting Standards Update 2016-13 | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Retained earnings | $ 822,000 | ||||
Decrease in allowance for credit losses | (1,300,000) | ||||
Increase in reserve on unfunded commitments | $ 499,000 |
Basis of Presentation - Effect
Basis of Presentation - Effect of Reclassifications on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Loans held for sale | $ 996,050 | $ 966,447 |
Loans and leases held for investment | 2,817,491 | 2,627,286 |
Allowance for credit losses on loans and leases | (35,906) | (28,234) |
Net loans and leases | 2,781,585 | 2,599,052 |
Total assets | $ 5,276,316 | 4,814,970 |
As Reported | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Loans held for sale | 966,447 | |
Loans and leases held for investment | 2,647,299 | |
Allowance for credit losses on loans and leases | (48,247) | |
Net loans and leases | 2,599,052 | |
Total assets | 4,814,970 | |
Restatement Adjustment | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Loans and leases held for investment | (20,013) | |
Allowance for credit losses on loans and leases | $ 20,013 |
Basis of Presentation - Effec_2
Basis of Presentation - Effect of Reclassifications on Consolidated Statements of Income (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | $ 11,792 | $ 3,031 |
Net interest income after provision for loan and lease credit losses | 28,369 | 27,574 |
Loan servicing asset revaluation | (4,692) | (4,040) |
Net (loss) gain on loans accounted for under the fair value option | (10,638) | 2,083 |
Total noninterest income | 5,742 | 13,316 |
Net (loss) income | $ (7,602) | 2,372 |
As Reported | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | 2,742 | |
Net interest income after provision for loan and lease credit losses | 27,863 | |
Loan servicing asset revaluation | (2,246) | |
Total noninterest income | 13,027 | |
Net (loss) income | 2,372 | |
Restatement Adjustment | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | 289 | |
Net interest income after provision for loan and lease credit losses | (289) | |
Loan servicing asset revaluation | (1,794) | |
Net (loss) gain on loans accounted for under the fair value option | 2,083 | |
Total noninterest income | $ 289 |
Basis of Presentation - Effec_3
Basis of Presentation - Effect of Reclassifications on Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | $ 11,792 | $ 3,031 |
Net decrease in servicing assets | 1,833 | 3,317 |
Net loss (gain) on loans accounted for under fair value option | 10,638 | (2,083) |
Net cash used by operating activities | (91,520) | (107,788) |
Loan and lease originations and principal collections, net | (152,559) | (113,064) |
Net cash used by investing activities | $ (179,226) | (300,927) |
As Reported | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | 2,742 | |
Net decrease in servicing assets | 3,317 | |
Change in discount on unguaranteed loans | (1,319) | |
Net cash used by operating activities | (107,313) | |
Loan and lease originations and principal collections, net | (113,539) | |
Net cash used by investing activities | (301,402) | |
Restatement Adjustment | ||
Error Corrections And Prior Period Adjustments Restatement [Line Items] | ||
Provision for loan and lease credit losses | 289 | |
Change in discount on unguaranteed loans | 1,319 | |
Net loss (gain) on loans accounted for under fair value option | (2,083) | |
Net cash used by operating activities | (475) | |
Loan and lease originations and principal collections, net | 475 | |
Net cash used by investing activities | $ 475 |
Earnings Per Share - Computatio
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Basic (loss) earnings per share: | ||
Net (loss attributable to) income available to common shareholders | $ (7,602) | $ 2,372 |
Weighted-average basic shares outstanding | 40,334,179 | 40,160,118 |
Basic (loss) earnings per share | $ (0.19) | $ 0.06 |
Diluted (loss) earnings per share: | ||
Net (loss attributable to) income available to common shareholders, for diluted (loss) earnings per share | $ (7,602) | $ 2,372 |
Weighted-average basic shares outstanding | 40,334,179 | 40,160,118 |
Add effect of dilutive stock options and restricted stock grants | 739,870 | 761,705 |
Total weighted-average diluted shares outstanding | 41,074,049 | 40,921,823 |
Diluted (loss) earnings per share | $ (0.19) | $ 0.06 |
Anti-dilutive shares | 1,839,601 | 1,597,589 |
Investment Securities - Carryin
Investment Securities - Carrying Amount and Fair Value of Investment Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | $ 550,814 | $ 524,619 |
Unrealized Gains | 23,919 | 16,361 |
Unrealized Losses | 565 | 935 |
Investment securities available-for-sale | 574,168 | 540,045 |
US Treasury Securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 4,992 | 4,988 |
Unrealized Gains | 51 | 27 |
Investment securities available-for-sale | 5,043 | 5,015 |
US government agencies | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 22,444 | 22,444 |
Unrealized Gains | 635 | 335 |
Investment securities available-for-sale | 23,079 | 22,779 |
Mortgage-backed securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 514,899 | 488,694 |
Unrealized Gains | 22,950 | 15,530 |
Unrealized Losses | 558 | 927 |
Investment securities available-for-sale | 537,291 | 503,297 |
Municipal bonds | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 8,479 | 8,493 |
Unrealized Gains | 283 | 469 |
Unrealized Losses | 7 | 8 |
Investment securities available-for-sale | $ 8,755 | $ 8,954 |
Investment Securities - Narrati
Investment Securities - Narrative (Details) | 3 Months Ended | ||
Mar. 31, 2020USD ($)Security | Mar. 31, 2019USD ($)Security | Dec. 31, 2019USD ($)Security | |
Schedule Of Available For Sale Securities [Line Items] | |||
(Loss) gain on sale of investment securities available-for-sale | $ (79,000) | $ 5,000 | |
Accrued interest receivable on available-for-sale securities | 1,800,000 | $ 1,600,000 | |
Other than temporary impairment losses | 0 | ||
Collateral Pledged | |||
Schedule Of Available For Sale Securities [Line Items] | |||
Debt securities, available-for-sale, restricted | $ 0 | $ 0 | |
Mortgage-backed securities | |||
Schedule Of Available For Sale Securities [Line Items] | |||
Number of investment securities sold | Security | 2 | ||
Proceeds from sale of investment securities | $ 4,500,000 | ||
Number of securities in unrealized loss portions for longer than 12 months | Security | 15 | 22 | |
Number of securities in unrealized loss positions for less than 12 months | Security | 12 | 20 | |
Municipal bonds | |||
Schedule Of Available For Sale Securities [Line Items] | |||
Number of investment securities sold | Security | 1 | ||
Proceeds from sale of investment securities | $ 900,000 | ||
Number of securities in unrealized loss portions for longer than 12 months | Security | 1 | 1 |
Investment Securities - Debt Se
Investment Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule Of Available For Sale Securities [Line Items] | ||
Securities in unrealized loss position, Less Than 12 Months, Fair Value | $ 36,320 | $ 42,835 |
Securities in unrealized loss position, Less Than 12 Months, Unrealized Losses | 213 | 460 |
Securities in unrealized loss position, 12 Months or More, Fair Value | 25,125 | 36,610 |
Securities in unrealized loss position, 12 Months or More, Unrealized Losses | 352 | 475 |
Securities in unrealized loss position, Total, Fair Value | 61,445 | 79,445 |
Securities in unrealized loss position, Total, Unrealized Losses | 565 | 935 |
Mortgage-backed securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Securities in unrealized loss position, Less Than 12 Months, Fair Value | 36,320 | 42,835 |
Securities in unrealized loss position, Less Than 12 Months, Unrealized Losses | 213 | 460 |
Securities in unrealized loss position, 12 Months or More, Fair Value | 25,032 | 36,518 |
Securities in unrealized loss position, 12 Months or More, Unrealized Losses | 345 | 467 |
Securities in unrealized loss position, Total, Fair Value | 61,352 | 79,353 |
Securities in unrealized loss position, Total, Unrealized Losses | 558 | 927 |
Municipal bonds | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Securities in unrealized loss position, 12 Months or More, Fair Value | 93 | 92 |
Securities in unrealized loss position, 12 Months or More, Unrealized Losses | 7 | 8 |
Securities in unrealized loss position, Total, Fair Value | 93 | 92 |
Securities in unrealized loss position, Total, Unrealized Losses | $ 7 | $ 8 |
Investment Securities - Summary
Investment Securities - Summary of Investment Securities by Maturity (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract] | ||
Amortized Cost | $ 550,814 | $ 524,619 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
Total, Fair value | 574,168 | 540,045 |
US Treasury Securities | ||
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract] | ||
Within one year, Amortized cost | 4,992 | |
Amortized Cost | 4,992 | 4,988 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
Within one year, Fair value | 5,043 | |
Total, Fair value | 5,043 | 5,015 |
US government agencies | ||
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract] | ||
Within one year, Amortized cost | 7,007 | |
One to five years, Amortized cost | 12,518 | |
Five to ten years, Amortized cost | 2,919 | |
Amortized Cost | 22,444 | 22,444 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
Within one year, Fair value | 7,070 | |
One to five years, Fair value | 12,901 | |
Five to ten years, Fair value | 3,108 | |
Total, Fair value | 23,079 | 22,779 |
Mortgage-backed securities | ||
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract] | ||
One to five years, Amortized cost | 4,700 | |
Five to ten years, Amortized cost | 178,652 | |
After 10 years, Amortized cost | 331,547 | |
Amortized Cost | 514,899 | 488,694 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
One to five years, Fair value | 4,853 | |
Five to ten years, Fair value | 191,718 | |
After 10 years, Fair value | 340,720 | |
Total, Fair value | 537,291 | 503,297 |
Municipal bonds | ||
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract] | ||
After 10 years, Amortized cost | 8,479 | |
Amortized Cost | 8,479 | 8,493 |
Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] | ||
After 10 years, Fair value | 8,755 | |
Total, Fair value | $ 8,755 | $ 8,954 |
Loans and Leases Held for Inv_3
Loans and Leases Held for Investment and Credit Quality - Summary of Total Loans and Leases and Aging Analysis of Portfolio Segments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | $ 42,525 | $ 27,893 |
Total Carried at Amortized Cost | 1,980,134 | 1,797,386 |
Loans Accounted for Under the Fair Value Option | 831,426 | 824,520 |
Total Loans and Leases | 2,811,560 | 2,621,906 |
Net Deferred Costs | 5,931 | 5,380 |
Loan and Leases, Net of unearned | 2,817,491 | 2,627,286 |
Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,937,609 | 1,769,493 |
30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 25,138 | 16,954 |
90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 17,387 | 10,939 |
Commercial & Industrial | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 19,431 | 13,248 |
Total Carried at Amortized Cost | 611,625 | 554,241 |
Loans Accounted for Under the Fair Value Option | 361,494 | 333,313 |
Total Loans and Leases | 973,119 | 887,554 |
Commercial & Industrial | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 592,194 | 540,993 |
Commercial & Industrial | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 12,472 | 7,895 |
Commercial & Industrial | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 6,959 | 5,353 |
Commercial & Industrial | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1 | |
Total Carried at Amortized Cost | 10,371 | 8,941 |
Loans Accounted for Under the Fair Value Option | 361 | 396 |
Total Loans and Leases | 10,732 | 9,337 |
Commercial & Industrial | Agriculture | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 10,370 | 8,941 |
Commercial & Industrial | Agriculture | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1 | |
Commercial & Industrial | Funeral Home & Cemetery | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 15,092 | 14,086 |
Loans Accounted for Under the Fair Value Option | 12,036 | 12,343 |
Total Loans and Leases | 27,128 | 26,429 |
Commercial & Industrial | Funeral Home & Cemetery | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 15,092 | 14,086 |
Commercial & Industrial | Healthcare | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 3,041 | 2,309 |
Total Carried at Amortized Cost | 29,918 | 24,055 |
Loans Accounted for Under the Fair Value Option | 19,826 | 20,999 |
Total Loans and Leases | 49,744 | 45,054 |
Commercial & Industrial | Healthcare | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 26,877 | 21,746 |
Commercial & Industrial | Healthcare | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,719 | 812 |
Commercial & Industrial | Healthcare | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,322 | 1,497 |
Commercial & Industrial | Independent Pharmacies | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 25,320 | 25,348 |
Loans Accounted for Under the Fair Value Option | 78,540 | 79,787 |
Total Loans and Leases | 103,860 | 105,135 |
Commercial & Industrial | Independent Pharmacies | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 25,320 | 25,348 |
Commercial & Industrial | Registered Investment Advisors | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 40,269 | 42,421 |
Loans Accounted for Under the Fair Value Option | 58,016 | 56,769 |
Total Loans and Leases | 98,285 | 99,190 |
Commercial & Industrial | Registered Investment Advisors | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 40,269 | 42,421 |
Commercial & Industrial | Veterinary Industry | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 481 | 504 |
Total Carried at Amortized Cost | 31,817 | 29,232 |
Loans Accounted for Under the Fair Value Option | 20,643 | 21,799 |
Total Loans and Leases | 52,460 | 51,031 |
Commercial & Industrial | Veterinary Industry | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 31,336 | 28,728 |
Commercial & Industrial | Veterinary Industry | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 481 | 504 |
Commercial & Industrial | Other Industries | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 15,908 | 10,435 |
Total Carried at Amortized Cost | 458,838 | 410,158 |
Loans Accounted for Under the Fair Value Option | 172,072 | 141,220 |
Total Loans and Leases | 630,910 | 551,378 |
Commercial & Industrial | Other Industries | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 442,930 | 399,723 |
Commercial & Industrial | Other Industries | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 10,271 | 6,579 |
Commercial & Industrial | Other Industries | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 5,637 | 3,856 |
Construction & Development | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 3,387 | |
Total Carried at Amortized Cost | 372,597 | 347,318 |
Total Loans and Leases | 372,597 | 347,318 |
Construction & Development | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 369,210 | 347,318 |
Construction & Development | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 3,387 | |
Construction & Development | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 45,333 | 44,571 |
Total Loans and Leases | 45,333 | 44,571 |
Construction & Development | Agriculture | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 45,333 | 44,571 |
Construction & Development | Funeral Home & Cemetery | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 9,146 | 9,033 |
Total Loans and Leases | 9,146 | 9,033 |
Construction & Development | Funeral Home & Cemetery | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 9,146 | 9,033 |
Construction & Development | Healthcare | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 3,387 | |
Total Carried at Amortized Cost | 100,791 | 94,742 |
Total Loans and Leases | 100,791 | 94,742 |
Construction & Development | Healthcare | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 97,404 | 94,742 |
Construction & Development | Healthcare | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 3,387 | |
Construction & Development | Independent Pharmacies | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 720 | 443 |
Total Loans and Leases | 720 | 443 |
Construction & Development | Independent Pharmacies | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 720 | 443 |
Construction & Development | Registered Investment Advisors | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 2,564 | 2,404 |
Total Loans and Leases | 2,564 | 2,404 |
Construction & Development | Registered Investment Advisors | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,564 | 2,404 |
Construction & Development | Veterinary Industry | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 20,862 | 22,132 |
Total Loans and Leases | 20,862 | 22,132 |
Construction & Development | Veterinary Industry | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 20,862 | 22,132 |
Construction & Development | Other Industries | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 193,181 | 173,993 |
Total Loans and Leases | 193,181 | 173,993 |
Construction & Development | Other Industries | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 193,181 | 173,993 |
Commercial Real Estate | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 17,537 | 14,645 |
Total Carried at Amortized Cost | 725,646 | 661,694 |
Loans Accounted for Under the Fair Value Option | 351,817 | 385,650 |
Total Loans and Leases | 1,077,463 | 1,047,344 |
Commercial Real Estate | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 708,109 | 647,049 |
Commercial Real Estate | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 9,279 | 9,059 |
Commercial Real Estate | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 8,258 | 5,586 |
Commercial Real Estate | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 1,291 | 30,066 |
Loans Accounted for Under the Fair Value Option | 762 | 19,975 |
Total Loans and Leases | 2,053 | 50,041 |
Commercial Real Estate | Agriculture | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,291 | 30,066 |
Commercial Real Estate | Funeral Home & Cemetery | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,817 | |
Total Carried at Amortized Cost | 58,699 | 55,243 |
Loans Accounted for Under the Fair Value Option | 58,611 | 58,171 |
Total Loans and Leases | 117,310 | 113,414 |
Commercial Real Estate | Funeral Home & Cemetery | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 58,699 | 53,426 |
Commercial Real Estate | Funeral Home & Cemetery | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,817 | |
Commercial Real Estate | Healthcare | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 4,498 | 4,498 |
Total Carried at Amortized Cost | 144,873 | 130,120 |
Loans Accounted for Under the Fair Value Option | 107,437 | 115,887 |
Total Loans and Leases | 252,310 | 246,007 |
Commercial Real Estate | Healthcare | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 140,375 | 125,622 |
Commercial Real Estate | Healthcare | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 4,498 | 4,498 |
Commercial Real Estate | Independent Pharmacies | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 822 | 930 |
Total Carried at Amortized Cost | 9,431 | 9,000 |
Loans Accounted for Under the Fair Value Option | 17,182 | 17,013 |
Total Loans and Leases | 26,613 | 26,013 |
Commercial Real Estate | Independent Pharmacies | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 8,609 | 8,070 |
Commercial Real Estate | Independent Pharmacies | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 930 | |
Commercial Real Estate | Independent Pharmacies | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 822 | |
Commercial Real Estate | Registered Investment Advisors | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Carried at Amortized Cost | 2,635 | 2,543 |
Loans Accounted for Under the Fair Value Option | 4,591 | 4,913 |
Total Loans and Leases | 7,226 | 7,456 |
Commercial Real Estate | Registered Investment Advisors | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,635 | 2,543 |
Commercial Real Estate | Veterinary Industry | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 4,042 | 2,815 |
Total Carried at Amortized Cost | 72,873 | 68,743 |
Loans Accounted for Under the Fair Value Option | 71,129 | 76,154 |
Total Loans and Leases | 144,002 | 144,897 |
Commercial Real Estate | Veterinary Industry | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 68,831 | 65,928 |
Commercial Real Estate | Veterinary Industry | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,953 | 1,727 |
Commercial Real Estate | Veterinary Industry | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,089 | 1,088 |
Commercial Real Estate | Other Industries | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 8,175 | 4,585 |
Total Carried at Amortized Cost | 435,844 | 365,979 |
Loans Accounted for Under the Fair Value Option | 92,105 | 93,537 |
Total Loans and Leases | 527,949 | 459,516 |
Commercial Real Estate | Other Industries | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 427,669 | 361,394 |
Commercial Real Estate | Other Industries | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 6,326 | 4,585 |
Commercial Real Estate | Other Industries | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 1,849 | |
Commercial Land | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,170 | |
Total Carried at Amortized Cost | 270,266 | 234,133 |
Loans Accounted for Under the Fair Value Option | 118,115 | 105,557 |
Total Loans and Leases | 388,381 | 339,690 |
Commercial Land | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 268,096 | 234,133 |
Commercial Land | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,170 | |
Commercial Land | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 2,170 | |
Total Carried at Amortized Cost | 270,266 | 234,133 |
Loans Accounted for Under the Fair Value Option | 118,115 | 105,557 |
Total Loans and Leases | 388,381 | 339,690 |
Commercial Land | Agriculture | Current or Less Than 30 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | 268,096 | $ 234,133 |
Commercial Land | Agriculture | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total Past Due | $ 2,170 |
Loans and Leases Held for Inv_4
Loans and Leases Held for Investment and Credit Quality - Summary of Total Loans and Leases and Aging Analysis of Portfolio Segments (Parenthetical) (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total loans and leases receivable | $ 1,980,134 | $ 1,797,386 |
Total past due loans | 42,525 | 27,893 |
90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total past due loans | 17,387 | 10,939 |
30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total past due loans | 25,138 | 16,954 |
Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total loans and leases receivable | 665,100 | 622,600 |
Current | 633,700 | 602,600 |
Loans Insured or Guaranteed by US Government Authorities | 90 Days or More Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total past due loans | 12,000 | 6,400 |
Loans Insured or Guaranteed by US Government Authorities | 30-89 Days Past Due | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Total past due loans | $ 19,400 | $ 13,600 |
Loans and Leases Held for Inv_5
Loans and Leases Held for Investment and Credit Quality - Summary of Asset Quality Indicators by Portfolio Segment and Origination Year (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | $ 151,414 | |
2019 | 603,868 | |
2018 | 428,207 | |
2017 | 351,501 | |
2016 | 206,798 | |
Prior | 124,521 | |
Revolving Loans Amortized Cost Basis | 112,947 | |
Revolving Loans Converted to Term | 878 | |
Total loans and leases | 1,980,134 | $ 1,797,386 |
Commercial & Industrial | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 71,188 | |
2019 | 270,987 | |
2018 | 93,658 | |
2017 | 47,974 | |
2016 | 12,455 | |
Prior | 5,902 | |
Revolving Loans Amortized Cost Basis | 108,755 | |
Revolving Loans Converted to Term | 706 | |
Total loans and leases | 611,625 | 554,241 |
Commercial & Industrial | Risk Grades 1 - 4 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 71,188 | |
2019 | 260,917 | |
2018 | 68,136 | |
2017 | 44,091 | |
2016 | 12,455 | |
Prior | 5,108 | |
Revolving Loans Amortized Cost Basis | 99,612 | |
Revolving Loans Converted to Term | 627 | |
Total loans and leases | 562,134 | 510,508 |
Commercial & Industrial | Risk Grade 5 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2019 | 6,770 | |
2018 | 14,554 | |
2017 | 31 | |
Prior | 313 | |
Revolving Loans Amortized Cost Basis | 8,201 | |
Revolving Loans Converted to Term | 79 | |
Total loans and leases | 29,948 | 32,462 |
Commercial & Industrial | Risk Grades 6 - 8 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2019 | 3,300 | |
2018 | 10,968 | |
2017 | 3,852 | |
Prior | 481 | |
Revolving Loans Amortized Cost Basis | 942 | |
Total loans and leases | 19,543 | 11,271 |
Construction & Development | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 18,172 | |
2019 | 141,380 | |
2018 | 146,175 | |
2017 | 53,118 | |
2016 | 11,128 | |
Prior | 449 | |
Revolving Loans Amortized Cost Basis | 2,175 | |
Total loans and leases | 372,597 | 347,318 |
Construction & Development | Risk Grades 1 - 4 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 18,172 | |
2019 | 141,380 | |
2018 | 138,387 | |
2017 | 43,656 | |
2016 | 11,128 | |
Prior | 449 | |
Revolving Loans Amortized Cost Basis | 2,175 | |
Total loans and leases | 355,347 | 331,135 |
Construction & Development | Risk Grade 5 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2018 | 7,788 | |
2017 | 8,758 | |
Total loans and leases | 16,546 | 15,477 |
Construction & Development | Risk Grades 6 - 8 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2017 | 704 | |
Total loans and leases | 704 | 706 |
Commercial Real Estate | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 56,428 | |
2019 | 160,097 | |
2018 | 133,896 | |
2017 | 194,727 | |
2016 | 117,049 | |
Prior | 61,260 | |
Revolving Loans Amortized Cost Basis | 2,017 | |
Revolving Loans Converted to Term | 172 | |
Total loans and leases | 725,646 | 661,694 |
Commercial Real Estate | Risk Grades 1 - 4 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 56,428 | |
2019 | 160,097 | |
2018 | 119,640 | |
2017 | 178,714 | |
2016 | 84,876 | |
Prior | 51,762 | |
Revolving Loans Amortized Cost Basis | 1,817 | |
Revolving Loans Converted to Term | 172 | |
Total loans and leases | 653,506 | 599,298 |
Commercial Real Estate | Risk Grade 5 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2018 | 14,256 | |
2017 | 7,767 | |
2016 | 22,351 | |
Prior | 5,098 | |
Revolving Loans Amortized Cost Basis | 200 | |
Total loans and leases | 49,672 | 41,573 |
Commercial Real Estate | Risk Grades 6 - 8 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2017 | 8,246 | |
2016 | 9,822 | |
Prior | 4,400 | |
Total loans and leases | 22,468 | 20,823 |
Commercial Land | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 5,626 | |
2019 | 31,404 | |
2018 | 54,478 | |
2017 | 55,682 | |
2016 | 66,166 | |
Prior | 56,910 | |
Total loans and leases | 270,266 | 234,133 |
Commercial Land | Risk Grades 1 - 4 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2020 | 5,626 | |
2019 | 31,404 | |
2018 | 54,474 | |
2017 | 55,682 | |
2016 | 66,166 | |
Prior | 52,576 | |
Total loans and leases | 265,928 | 227,377 |
Commercial Land | Risk Grades 6 - 8 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
2018 | 4 | |
Prior | 4,334 | |
Total loans and leases | $ 4,338 | $ 6,756 |
Loans and Leases Held for Inv_6
Loans and Leases Held for Investment and Credit Quality - Summary of Asset Quality Indicators by Portfolio Segment and Origination Year (Parenthetical) (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment [Line Items] | ||
Total loans and leases | $ 1,980,134 | $ 1,797,386 |
Loans receivable, fair value | 831,426 | 824,520 |
Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Total loans and leases | 665,100 | 622,600 |
Loans Insured or Guaranteed by US Government Authorities | Risk Grades 1 - 4 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Total loans and leases | 584,500 | 556,800 |
Loans Insured or Guaranteed by US Government Authorities | Risk Grade 5 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Total loans and leases | 50,000 | 42,700 |
Loans Insured or Guaranteed by US Government Authorities | Risk Grades 6 - 8 | ||
Financing Receivable, Recorded Investment [Line Items] | ||
Total loans and leases | $ 30,600 | $ 23,100 |
Loans and Leases Held for Inv_7
Loans and Leases Held for Investment and Credit Quality - Additional Information (Details) | 3 Months Ended | ||
Mar. 31, 2020USD ($)SecurityLoan | Dec. 31, 2019USD ($) | Mar. 31, 2019SecurityLoan | |
Receivables [Abstract] | |||
Interest income recognized on nonaccrual loans and leases | $ 0 | $ 0 | |
Accrued interest receivable on loans | $ 20,800,000 | $ 19,800,000 | |
Number of TDRs with subsequent default | SecurityLoan | 0 | 0 |
Loans and Leases Held for Inv_8
Loans and Leases Held for Investment and Credit Quality - Nonaccrual Loans and Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | $ 34,088 | $ 21,939 |
Unguaranteed Exposure with No ACL | 1,873 | |
Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 24,465 | 14,714 |
Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 9,623 | 7,225 |
Commercial & Industrial | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 16,222 | 6,938 |
Commercial & Industrial | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 12,886 | 5,556 |
Commercial & Industrial | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 3,336 | 1,382 |
Commercial & Industrial | Healthcare | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 2,099 | 2,309 |
Commercial & Industrial | Healthcare | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1,905 | 1,931 |
Commercial & Industrial | Healthcare | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 194 | 378 |
Commercial & Industrial | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1 | 269 |
Commercial & Industrial | Agriculture | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1 | 215 |
Commercial & Industrial | Agriculture | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 54 | |
Commercial & Industrial | Independent Pharmacies | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 4,424 | |
Commercial & Industrial | Independent Pharmacies | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 3,318 | |
Commercial & Industrial | Independent Pharmacies | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1,106 | |
Commercial & Industrial | Veterinary Industry | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 481 | 504 |
Commercial & Industrial | Veterinary Industry | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 481 | 504 |
Commercial & Industrial | Other Industries | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 9,217 | 3,856 |
Commercial & Industrial | Other Industries | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 7,181 | 2,906 |
Commercial & Industrial | Other Industries | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 2,036 | 950 |
Commercial Real Estate | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 13,529 | 8,245 |
Unguaranteed Exposure with No ACL | 1,841 | |
Commercial Real Estate | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 8,174 | 4,130 |
Commercial Real Estate | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 5,355 | 4,115 |
Commercial Real Estate | Healthcare | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 4,498 | 4,498 |
Unguaranteed Exposure with No ACL | 1,841 | |
Commercial Real Estate | Healthcare | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1,254 | 1,254 |
Commercial Real Estate | Healthcare | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 3,244 | 3,244 |
Commercial Real Estate | Independent Pharmacies | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 822 | 931 |
Commercial Real Estate | Independent Pharmacies | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 698 | 698 |
Commercial Real Estate | Independent Pharmacies | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 124 | 233 |
Commercial Real Estate | Veterinary Industry | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 2,770 | 2,816 |
Commercial Real Estate | Veterinary Industry | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 2,143 | 2,178 |
Commercial Real Estate | Veterinary Industry | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 627 | 638 |
Commercial Real Estate | Other Industries | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 5,439 | |
Commercial Real Estate | Other Industries | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 4,079 | |
Commercial Real Estate | Other Industries | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 1,360 | |
Commercial Land | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 4,337 | 6,756 |
Unguaranteed Exposure with No ACL | 32 | |
Commercial Land | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 3,405 | 5,028 |
Commercial Land | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 932 | 1,728 |
Commercial Land | Agriculture | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 4,337 | 6,756 |
Unguaranteed Exposure with No ACL | 32 | |
Commercial Land | Agriculture | Loans Insured or Guaranteed by US Government Authorities | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | 3,405 | 5,028 |
Commercial Land | Agriculture | Unguaranteed Balance | ||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
Nonaccrual loan balance | $ 932 | $ 1,728 |
Loans and Leases Held for Inv_9
Loans and Leases Held for Investment and Credit Quality - Amortized Cost Basis of Collateral-Dependent Loans and Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | $ 1,980,134 | $ 1,797,386 | ||
Allowance for Credit Losses | 35,906 | 28,234 | $ 17,550 | $ 14,432 |
Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 21,021 | |||
Collateral Dependent Loans, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 6,959 | |||
Collateral Dependent Loans, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 2,148 | |||
Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 6,325 | |||
Unguaranteed Portion, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,756 | |||
Unguaranteed Portion, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 148 | |||
Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 2,803 | |||
Commercial & Industrial | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 611,625 | 554,241 | ||
Allowance for Credit Losses | 16,337 | 15,757 | 8,282 | 6,524 |
Commercial & Industrial | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 5,774 | |||
Commercial & Industrial | Collateral Dependent Loans, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 6,959 | |||
Commercial & Industrial | Collateral Dependent Loans, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 2,148 | |||
Commercial & Industrial | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,404 | |||
Commercial & Industrial | Unguaranteed Portion, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,756 | |||
Commercial & Industrial | Unguaranteed Portion, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 148 | |||
Commercial & Industrial | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 2,288 | |||
Commercial & Industrial | Healthcare | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 29,918 | 24,055 | ||
Commercial & Industrial | Healthcare | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,188 | |||
Commercial & Industrial | Healthcare | Collateral Dependent Loans, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 178 | |||
Commercial & Industrial | Healthcare | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 41 | |||
Commercial & Industrial | Healthcare | Unguaranteed Portion, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 3 | |||
Commercial & Industrial | Healthcare | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 44 | |||
Commercial & Industrial | Independent Pharmacies | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 25,320 | 25,348 | ||
Commercial & Industrial | Independent Pharmacies | Collateral Dependent Loans, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 4,514 | |||
Commercial & Industrial | Independent Pharmacies | Unguaranteed Portion, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,196 | |||
Commercial & Industrial | Independent Pharmacies | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 1,177 | |||
Commercial & Industrial | Other Industries | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 458,838 | 410,158 | ||
Commercial & Industrial | Other Industries | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 4,586 | |||
Commercial & Industrial | Other Industries | Collateral Dependent Loans, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 2,267 | |||
Commercial & Industrial | Other Industries | Collateral Dependent Loans, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 2,148 | |||
Commercial & Industrial | Other Industries | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,363 | |||
Commercial & Industrial | Other Industries | Unguaranteed Portion, Business Assets | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 557 | |||
Commercial & Industrial | Other Industries | Unguaranteed Portion, Other | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 148 | |||
Commercial & Industrial | Other Industries | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 1,067 | |||
Commercial & Industrial | Veterinary Industry | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 31,817 | 29,232 | ||
Commercial & Industrial | Agriculture | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 10,371 | 8,941 | ||
Commercial Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 725,646 | 661,694 | ||
Allowance for Credit Losses | 13,110 | 8,427 | 5,379 | 5,259 |
Commercial Real Estate | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 10,888 | |||
Commercial Real Estate | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 3,969 | |||
Commercial Real Estate | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 187 | |||
Commercial Real Estate | Healthcare | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 144,873 | 130,120 | ||
Commercial Real Estate | Healthcare | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,821 | |||
Commercial Real Estate | Healthcare | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,821 | |||
Commercial Real Estate | Independent Pharmacies | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 9,431 | 9,000 | ||
Commercial Real Estate | Independent Pharmacies | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 826 | |||
Commercial Real Estate | Independent Pharmacies | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 128 | |||
Commercial Real Estate | Independent Pharmacies | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 4 | |||
Commercial Real Estate | Other Industries | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 435,844 | 365,979 | ||
Commercial Real Estate | Other Industries | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 5,449 | |||
Commercial Real Estate | Other Industries | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,371 | |||
Commercial Real Estate | Other Industries | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 3 | |||
Commercial Real Estate | Veterinary Industry | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 72,873 | 68,743 | ||
Commercial Real Estate | Veterinary Industry | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 2,792 | |||
Commercial Real Estate | Veterinary Industry | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 649 | |||
Commercial Real Estate | Veterinary Industry | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 180 | |||
Commercial Real Estate | Agriculture | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 1,291 | 30,066 | ||
Commercial Land | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 270,266 | 234,133 | ||
Allowance for Credit Losses | 1,636 | 1,318 | $ 1,653 | $ 607 |
Commercial Land | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 4,359 | |||
Commercial Land | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 952 | |||
Commercial Land | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | 328 | |||
Commercial Land | Agriculture | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 270,266 | $ 234,133 | ||
Commercial Land | Agriculture | Collateral Dependent Loans, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 4,359 | |||
Commercial Land | Agriculture | Unguaranteed Portion, Real Estate | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Total loans and leases receivable | 952 | |||
Commercial Land | Agriculture | Unguaranteed Portion | ||||
Financing Receivable, Recorded Investment, Past Due [Line Items] | ||||
Allowance for Credit Losses | $ 328 |
Loans and Leases Held for In_10
Loans and Leases Held for Investment and Credit Quality - Activity in the ACL by Portfolio Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Allowance for Loan Losses: | ||
Beginning Balance, prior to adoption of ASC 326 | $ 28,234 | $ 14,432 |
Impact of adopting ASC 326 | (1,321) | |
Charge offs | (2,862) | |
Recoveries | 63 | 87 |
Provision | 11,792 | 3,031 |
Ending Balance | 35,906 | 17,550 |
Construction & Development | ||
Allowance for Loan Losses: | ||
Beginning Balance, prior to adoption of ASC 326 | 2,732 | 2,042 |
Impact of adopting ASC 326 | 1,131 | |
Provision | 960 | 194 |
Ending Balance | 4,823 | 2,236 |
Commercial Real Estate | ||
Allowance for Loan Losses: | ||
Beginning Balance, prior to adoption of ASC 326 | 8,427 | 5,259 |
Impact of adopting ASC 326 | 1,916 | |
Charge offs | (109) | |
Recoveries | 28 | 8 |
Provision | 2,848 | 112 |
Ending Balance | 13,110 | 5,379 |
Commercial & Industrial | ||
Allowance for Loan Losses: | ||
Beginning Balance, prior to adoption of ASC 326 | 15,757 | 6,524 |
Impact of adopting ASC 326 | (4,561) | |
Charge offs | (2,345) | |
Recoveries | 35 | 79 |
Provision | 7,451 | 1,679 |
Ending Balance | 16,337 | 8,282 |
Commercial Land | ||
Allowance for Loan Losses: | ||
Beginning Balance, prior to adoption of ASC 326 | 1,318 | 607 |
Impact of adopting ASC 326 | 193 | |
Charge offs | (408) | |
Provision | 533 | 1,046 |
Ending Balance | $ 1,636 | $ 1,653 |
Loans and Leases Held for In_11
Loans and Leases Held for Investment and Credit Quality - Schedule of Troubled Debt Restructurings (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020USD ($)SecurityLoan | Mar. 31, 2019USD ($)SecurityLoan | |
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 4 | 2 |
Recorded investment at period end | $ | $ 6,049 | $ 5,342 |
Extended Amortization | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 1 | 1 |
Recorded investment at period end | $ | $ 973 | $ 3,489 |
Extended Amortization | Commercial Land | Agriculture | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 1 | |
Recorded investment at period end | $ | $ 3,489 | |
Extended Amortization | Commercial & Industrial | Other Industries | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 1 | |
Recorded investment at period end | $ | $ 973 | |
Payment Deferral | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 3 | 1 |
Recorded investment at period end | $ | $ 5,076 | $ 1,853 |
Payment Deferral | Commercial & Industrial | Other Industries | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 2 | |
Recorded investment at period end | $ | $ 1,487 | |
Payment Deferral | Commercial Real Estate | Other Industries | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 1 | |
Recorded investment at period end | $ | $ 3,589 | |
Payment Deferral | Commercial Real Estate | Healthcare | ||
Financing Receivable, Modifications [Line Items] | ||
Number of Loans | SecurityLoan | 1 | |
Recorded investment at period end | $ | $ 1,853 |
Loans and Leases Held for In_12
Loans and Leases Held for Investment and Credit Quality - Recorded Allowance for Loan Loans Receivable (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Allowance for loan and lease losses: | ||
Loans and leases individually evaluated for impairment | $ 6,821 | |
Loans and leases collectively evaluated for impairment | 21,413 | |
Total allowance for loan and lease losses | $ 35,906 | 28,234 |
Loans and leases receivable: | ||
Loans and leases individually evaluated for impairment | 57,507 | |
Loans and leases collectively evaluated for impairment | 1,739,879 | |
Total loans and leases receivable | 1,980,134 | 1,797,386 |
Construction & Development | ||
Allowance for loan and lease losses: | ||
Loans and leases individually evaluated for impairment | 17 | |
Loans and leases collectively evaluated for impairment | 2,715 | |
Total allowance for loan and lease losses | 2,732 | |
Loans and leases receivable: | ||
Loans and leases individually evaluated for impairment | 719 | |
Loans and leases collectively evaluated for impairment | 346,599 | |
Total loans and leases receivable | 372,597 | 347,318 |
Commercial Real Estate | ||
Allowance for loan and lease losses: | ||
Loans and leases individually evaluated for impairment | 2,067 | |
Loans and leases collectively evaluated for impairment | 6,360 | |
Total allowance for loan and lease losses | 8,427 | |
Loans and leases receivable: | ||
Loans and leases individually evaluated for impairment | 25,389 | |
Loans and leases collectively evaluated for impairment | 636,305 | |
Total loans and leases receivable | 725,646 | 661,694 |
Commercial & Industrial | ||
Allowance for loan and lease losses: | ||
Loans and leases individually evaluated for impairment | 3,989 | |
Loans and leases collectively evaluated for impairment | 11,768 | |
Total allowance for loan and lease losses | 15,757 | |
Loans and leases receivable: | ||
Loans and leases individually evaluated for impairment | 14,052 | |
Loans and leases collectively evaluated for impairment | 540,189 | |
Total loans and leases receivable | 611,625 | 554,241 |
Commercial Land | ||
Allowance for loan and lease losses: | ||
Loans and leases individually evaluated for impairment | 748 | |
Loans and leases collectively evaluated for impairment | 570 | |
Total allowance for loan and lease losses | 1,318 | |
Loans and leases receivable: | ||
Loans and leases individually evaluated for impairment | 17,347 | |
Loans and leases collectively evaluated for impairment | 216,786 | |
Total loans and leases receivable | $ 270,266 | $ 234,133 |
Loans and Leases Held for In_13
Loans and Leases Held for Investment and Credit Quality - Recorded Allowance for Loan Loans Receivable (Parenthetical) (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Allowance for Loan Losses: | ||
Total loans and leases receivable | $ 1,980,134 | $ 1,797,386 |
Loans and leases individually evaluated for impairment | 57,507 | |
Loans receivable, fair value | 831,426 | 824,520 |
Loans Insured or Guaranteed by US Government Authorities | ||
Allowance for Loan Losses: | ||
Total loans and leases receivable | $ 665,100 | 622,600 |
Loans and leases individually evaluated for impairment | $ 36,000 |
Loans and Leases Held for In_14
Loans and Leases Held for Investment and Credit Quality - Loans and Leases Classified as Impaired (Details) $ in Thousands | Dec. 31, 2019USD ($) |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | $ 57,507 |
Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 36,011 |
Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 21,496 |
Commercial & Industrial | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 14,052 |
Commercial & Industrial | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 7,998 |
Commercial & Industrial | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 6,054 |
Commercial & Industrial | Agriculture | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 367 |
Commercial & Industrial | Agriculture | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 215 |
Commercial & Industrial | Agriculture | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 152 |
Commercial & Industrial | Healthcare | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 3,760 |
Commercial & Industrial | Healthcare | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 1,931 |
Commercial & Industrial | Healthcare | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 1,829 |
Commercial & Industrial | Veterinary Industry | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 504 |
Commercial & Industrial | Veterinary Industry | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 504 |
Commercial & Industrial | Other Industries | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 9,421 |
Commercial & Industrial | Other Industries | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 5,348 |
Commercial & Industrial | Other Industries | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 4,073 |
Construction & Development | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 719 |
Construction & Development | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 530 |
Construction & Development | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 189 |
Construction & Development | Healthcare | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 719 |
Construction & Development | Healthcare | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 530 |
Construction & Development | Healthcare | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 189 |
Commercial Real Estate | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 25,389 |
Commercial Real Estate | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 14,585 |
Commercial Real Estate | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 10,804 |
Commercial Real Estate | Healthcare | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 12,677 |
Commercial Real Estate | Healthcare | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 5,101 |
Commercial Real Estate | Healthcare | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 7,576 |
Commercial Real Estate | Veterinary Industry | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 5,907 |
Commercial Real Estate | Veterinary Industry | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 4,707 |
Commercial Real Estate | Veterinary Industry | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 1,200 |
Commercial Real Estate | Other Industries | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 5,872 |
Commercial Real Estate | Other Industries | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 4,079 |
Commercial Real Estate | Other Industries | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 1,793 |
Commercial Real Estate | Independent Pharmacies | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 933 |
Commercial Real Estate | Independent Pharmacies | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 698 |
Commercial Real Estate | Independent Pharmacies | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 235 |
Commercial Land | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 17,347 |
Commercial Land | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 12,898 |
Commercial Land | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 4,449 |
Commercial Land | Agriculture | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 17,347 |
Commercial Land | Agriculture | Loans Insured or Guaranteed by US Government Authorities | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | 12,898 |
Commercial Land | Agriculture | Unguaranteed Exposure | |
Financing Receivable, Impaired [Line Items] | |
Impaired loans | $ 4,449 |
Loans and Leases Held for In_15
Loans and Leases Held for Investment and Credit Quality - Impaired Loans and Leases With Associated Reserves and No Associated Reserves (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2019 | |
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | $ 55,399 | |
Recorded Investment, With No Recorded Allowance | 2,108 | |
Recorded Investment, Total | 57,507 | |
Loans, Unpaid Principal Balance | 58,833 | |
Loans, Related Allowance Recorded | 6,821 | |
Loans, Average Balance | $ 47,809 | |
Loans, Interest Income Recognized | 385 | |
Commercial & Industrial | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 14,047 | |
Recorded Investment, With No Recorded Allowance | 5 | |
Recorded Investment, Total | 14,052 | |
Loans, Unpaid Principal Balance | 14,884 | |
Loans, Related Allowance Recorded | 3,989 | |
Loans, Average Balance | 8,662 | |
Loans, Interest Income Recognized | 47 | |
Commercial & Industrial | Agriculture | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 362 | |
Recorded Investment, With No Recorded Allowance | 5 | |
Recorded Investment, Total | 367 | |
Loans, Unpaid Principal Balance | 378 | |
Loans, Related Allowance Recorded | 95 | |
Loans, Average Balance | 6 | |
Commercial & Industrial | Healthcare | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 3,760 | |
Recorded Investment, Total | 3,760 | |
Loans, Unpaid Principal Balance | 4,109 | |
Loans, Related Allowance Recorded | 975 | |
Loans, Average Balance | 4,492 | |
Loans, Interest Income Recognized | 29 | |
Commercial & Industrial | Veterinary Industry | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 504 | |
Recorded Investment, Total | 504 | |
Loans, Unpaid Principal Balance | 672 | |
Loans, Related Allowance Recorded | 4 | |
Loans, Average Balance | 632 | |
Loans, Interest Income Recognized | 1 | |
Commercial & Industrial | Other Industries | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 9,421 | |
Recorded Investment, Total | 9,421 | |
Loans, Unpaid Principal Balance | 9,725 | |
Loans, Related Allowance Recorded | 2,915 | |
Loans, Average Balance | 3,532 | |
Loans, Interest Income Recognized | 17 | |
Construction & Development | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 719 | |
Recorded Investment, Total | 719 | |
Loans, Unpaid Principal Balance | 706 | |
Loans, Related Allowance Recorded | 17 | |
Construction & Development | Healthcare | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 719 | |
Recorded Investment, Total | 719 | |
Loans, Unpaid Principal Balance | 706 | |
Loans, Related Allowance Recorded | 17 | |
Commercial Real Estate | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 23,286 | |
Recorded Investment, With No Recorded Allowance | 2,103 | |
Recorded Investment, Total | 25,389 | |
Loans, Unpaid Principal Balance | 25,844 | |
Loans, Related Allowance Recorded | 2,067 | |
Loans, Average Balance | 17,642 | |
Loans, Interest Income Recognized | 142 | |
Commercial Real Estate | Healthcare | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 10,835 | |
Recorded Investment, With No Recorded Allowance | 1,842 | |
Recorded Investment, Total | 12,677 | |
Loans, Unpaid Principal Balance | 12,602 | |
Loans, Related Allowance Recorded | 1,579 | |
Loans, Average Balance | 9,772 | |
Loans, Interest Income Recognized | 101 | |
Commercial Real Estate | Veterinary Industry | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 5,907 | |
Recorded Investment, Total | 5,907 | |
Loans, Unpaid Principal Balance | 6,615 | |
Loans, Related Allowance Recorded | 311 | |
Loans, Average Balance | 6,282 | |
Loans, Interest Income Recognized | 41 | |
Commercial Real Estate | Other Industries | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 5,611 | |
Recorded Investment, With No Recorded Allowance | 261 | |
Recorded Investment, Total | 5,872 | |
Loans, Unpaid Principal Balance | 5,697 | |
Loans, Related Allowance Recorded | 89 | |
Loans, Average Balance | 1,588 | |
Commercial Real Estate | Independent Pharmacies | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 933 | |
Recorded Investment, Total | 933 | |
Loans, Unpaid Principal Balance | 930 | |
Loans, Related Allowance Recorded | 88 | |
Commercial Land | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 17,347 | |
Recorded Investment, Total | 17,347 | |
Loans, Unpaid Principal Balance | 17,399 | |
Loans, Related Allowance Recorded | 748 | |
Loans, Average Balance | 21,505 | |
Loans, Interest Income Recognized | 196 | |
Commercial Land | Agriculture | ||
Financing Receivable, Impaired [Line Items] | ||
Recorded Investment, With a Recorded Allowance | 17,347 | |
Recorded Investment, Total | 17,347 | |
Loans, Unpaid Principal Balance | 17,399 | |
Loans, Related Allowance Recorded | $ 748 | |
Loans, Average Balance | 21,505 | |
Loans, Interest Income Recognized | $ 196 |
Leases - Additional Information
Leases - Additional Information (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020USD ($)term | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($) | |
Lessor Lease Description [Line Items] | |||
Direct financing lease, interest income | $ 233 | $ 234 | |
Number of additional terms | term | 2 | ||
Premises and equipment, net | $ 274,177 | $ 279,099 | |
Lease income | 2,400 | 2,300 | |
Premises and Equipment Subject to Operating Leases | |||
Lessor Lease Description [Line Items] | |||
Premises and equipment, net | 141,800 | 144,300 | |
Premises and equipment, gross | 164,300 | 164,300 | |
Premises and equipment, accumulated depreciation | 22,500 | $ 20,000 | |
Premises and equipment, depreciation expense | $ 2,500 | $ 2,400 | |
Minimum | |||
Lessor Lease Description [Line Items] | |||
Lessor, term of contract | 3 years | ||
Term of contract | 10 years | ||
Useful life | 20 years | ||
Residual value (as a percent) | 20.00% | ||
Maximum | |||
Lessor Lease Description [Line Items] | |||
Lessor, term of contract | 7 years | ||
Term of contract | 15 years | ||
Useful life | 25 years | ||
Residual value (as a percent) | 50.00% |
Leases - Direct Financing Lease
Leases - Direct Financing Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Gross direct finance lease payments receivable | $ 13,197 | $ 13,959 |
Less – unearned interest | (2,334) | (2,562) |
Net investment in direct financing leases | $ 10,863 | $ 11,397 |
Leases - Finance Lease Maturity
Leases - Finance Lease Maturity (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
2020 | $ 2,367 | |
2021 | 2,928 | |
2022 | 2,699 | |
2023 | 2,259 | |
2024 | 1,635 | |
Thereafter | 1,309 | |
Total | $ 13,197 | $ 13,959 |
Leases - Maturity Analysis of F
Leases - Maturity Analysis of Future Minimum Operating Lease Payments (Details) $ in Thousands | Mar. 31, 2020USD ($) |
Leases [Abstract] | |
2020 | $ 7,060 |
2021 | 9,052 |
2022 | 9,044 |
2023 | 9,075 |
2024 | 8,808 |
Thereafter | 40,110 |
Total | $ 83,149 |
Servicing Assets - Narrative (D
Servicing Assets - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Servicing Assets at Fair Value [Line Items] | |||
Unpaid principal balance of loans serviced for others requiring recognition of a servicing asset | $ 2,220 | $ 2,260 | |
Unpaid principal balances of loan serviced for others | $ 2,980 | $ 2,970 | |
Weighted Average | |||
Servicing Assets at Fair Value [Line Items] | |||
Fair value of servicing rights, discount rate | 13.00% | 14.70% | |
Fair value of servicing rights, prepayment rate | 17.90% | 13.10% |
Servicing Assets - Summary of A
Servicing Assets - Summary of Activity Pertaining to Servicing Rights (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Servicing Asset At Fair Value Amount Roll Forward | ||
Balance at beginning of period | $ 35,365 | $ 47,641 |
Additions, net | 2,859 | 723 |
Fair value changes: | ||
Due to changes in valuation inputs or assumptions | (2,039) | (524) |
Decay due to increases in principal paydowns or runoff | (2,653) | (3,516) |
Balance at end of period | $ 33,532 | $ 44,324 |
Borrowings - Total Outstanding
Borrowings - Total Outstanding Borrowings (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Borrowings | $ 50,012 | $ 14 |
Revolving Line of Credit | ||
Debt Instrument [Line Items] | ||
Borrowings | 50,000 | |
Financing Lease Obligations | ||
Debt Instrument [Line Items] | ||
Borrowings | $ 12 | $ 14 |
Borrowings - Total Outstandin_2
Borrowings - Total Outstanding Borrowings (Parenthetical) (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Dec. 31, 2019 | Oct. 31, 2017 | |
Debt Instrument [Line Items] | |||
Borrowings | $ 50,012,000 | $ 14,000 | |
Revolving Line of Credit | |||
Debt Instrument [Line Items] | |||
Debt instrument term | 13 months | ||
Borrowings | $ 50,000,000 | ||
Current available credit facility | $ 0 | ||
Debt instrument, maturity date | Oct. 20, 2020 | ||
Line of Credit | London Interbank Offered Rate (LIBOR) | Revolving Line of Credit | |||
Debt Instrument [Line Items] | |||
Basis spread on variable rate | 1.15% | ||
Financing Lease Obligations | |||
Debt Instrument [Line Items] | |||
Borrowings | $ 12,000 | $ 14,000 | |
Financing Lease Obligations | Finance Lease with Unaffiliated Lease Company | |||
Debt Instrument [Line Items] | |||
Finance lease obligations, noncurrent | $ 19,000 | ||
Term of contract | 60 months | ||
Option to purchase equipment, amount | $ 1 |
Borrowings - Narrative (Details
Borrowings - Narrative (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Repurchased agreements, borrowing capacity | $ 5,000,000 | $ 5,000,000 |
Repurchases agreements, outstanding balance | 0 | 0 |
FHLB maximum amount available | 1,200,000,000 | 1,140,000,000 |
Federal Funds Purchased | ||
Debt Instrument [Line Items] | ||
Line of credit, maximum borrowing capacity | 72,500,000 | 72,500,000 |
Short term borrowings | 0 | 0 |
Federal Reserve Bank Advances | Federal Reserve Bank | ||
Debt Instrument [Line Items] | ||
Collateral amount | 565,800,000 | 526,800,000 |
Remaining available credit facility | 309,100,000 | 294,500,000 |
Short term borrowings | $ 0 | $ 0 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Recorded Amount of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | $ 574,168 | $ 540,045 | ||
Loans held for sale | 19,151 | 16,198 | ||
Loans held for investment | 831,426 | 824,520 | ||
Servicing assets | 33,532 | 35,365 | $ 44,324 | $ 47,641 |
US Treasury Securities | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 5,043 | 5,015 | ||
US government agencies | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 23,079 | 22,779 | ||
Mortgage-backed securities | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 537,291 | 503,297 | ||
Recurring | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Loans held for sale | 19,151 | 16,198 | ||
Loans held for investment | 831,426 | 824,520 | ||
Servicing assets | 33,532 | 35,365 | ||
Equity warrant assets | 702 | 570 | ||
Total assets at fair value | 1,461,120 | 1,418,904 | ||
Recurring | Municipal bonds | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 8,755 | 8,954 | ||
Recurring | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Servicing assets | 0 | 0 | ||
Equity warrant assets | 0 | 0 | ||
Total assets at fair value | 0 | 0 | ||
Recurring | Level 1 | Municipal bonds | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Servicing assets | 0 | 0 | ||
Equity warrant assets | 0 | 0 | ||
Total assets at fair value | 576,216 | 542,159 | ||
Recurring | Level 2 | Municipal bonds | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 8,662 | 8,862 | ||
Recurring | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Loans held for sale | 19,151 | 16,198 | ||
Loans held for investment | 831,426 | 824,520 | ||
Servicing assets | 33,532 | 35,365 | ||
Equity warrant assets | 702 | 570 | ||
Total assets at fair value | 884,904 | 876,745 | ||
Recurring | Level 3 | Municipal bonds | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 93 | 92 | ||
Total assets at fair value | 93 | 92 | ||
Recurring | US Treasury Securities | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 5,043 | 5,015 | ||
Recurring | US Treasury Securities | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | US Treasury Securities | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 5,043 | 5,015 | ||
Recurring | US Treasury Securities | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | US government agencies | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 23,079 | 22,779 | ||
Recurring | US government agencies | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | US government agencies | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 23,079 | 22,779 | ||
Recurring | US government agencies | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | Mortgage-backed securities | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 537,291 | 503,297 | ||
Recurring | Mortgage-backed securities | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | Mortgage-backed securities | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 537,291 | 503,297 | ||
Recurring | Mortgage-backed securities | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Investment securities available-for-sale | 0 | 0 | ||
Recurring | Mutual Fund | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Mutual fund | 2,141 | 2,206 | ||
Recurring | Mutual Fund | Level 1 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Mutual fund | 0 | 0 | ||
Recurring | Mutual Fund | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Mutual fund | 2,141 | 2,206 | ||
Recurring | Mutual Fund | Level 3 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Mutual fund | $ 0 | $ 0 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Recorded Amount of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investment securities available-for-sale with value | $ 900 | |
Equity Warrant Assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Equity warrant assets, fair value | $ 164 | |
Gain (loss) on derivative, net | (32) | 255 |
Municipal bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value adjustment gain (loss) | $ 1 | $ (9) |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Additional Information (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Fair Value Disclosures [Abstract] | |||
Fair value option that were 90 days or more past due and still accruing | $ 0 | $ 0 | |
Unpaid principal balance of unguaranteed exposure for nonaccruals | 12,200,000 | $ 10,700,000 | |
Loss related to borrower specific credit risk | $ 922,000 | $ 522,000 |
Fair Value of Financial Instr_6
Fair Value of Financial Instruments - Summary of Fair Value Carrying Amount and Unpaid Principal Outstanding of Loans Under Fair Value Option (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value Option Quantitative Disclosures [Line Items] | ||
Total Loans, Fair Value Carrying amount | $ 850,577 | $ 840,718 |
Total Loans, Unpaid Principal Balance | 878,633 | 859,686 |
Total Loans, Difference | (28,056) | (18,968) |
Nonaccruals, Fair Value Carrying amount | 60,558 | 49,739 |
Nonaccruals, Unpaid Principal Balance | 65,303 | 54,370 |
Nonaccruals, Difference | (4,745) | (4,631) |
90 Days or More Past Due, Fair Value Carrying Amount | 39,102 | 26,644 |
90 Days or More Past Due, Unpaid Principal Balance | 40,876 | 28,137 |
90 Days or More Past Due, Difference | (1,774) | (1,493) |
Loans held for sale | ||
Fair Value Option Quantitative Disclosures [Line Items] | ||
Total Loans, Fair Value Carrying amount | 19,151 | 16,198 |
Total Loans, Unpaid Principal Balance | 20,056 | 17,230 |
Total Loans, Difference | (905) | (1,032) |
Loans held for investment | ||
Fair Value Option Quantitative Disclosures [Line Items] | ||
Total Loans, Fair Value Carrying amount | 831,426 | 824,520 |
Total Loans, Unpaid Principal Balance | 858,577 | 842,456 |
Total Loans, Difference | (27,151) | (17,936) |
Nonaccruals, Fair Value Carrying amount | 60,558 | 49,739 |
Nonaccruals, Unpaid Principal Balance | 65,303 | 54,370 |
Nonaccruals, Difference | (4,745) | (4,631) |
90 Days or More Past Due, Fair Value Carrying Amount | 39,102 | 26,644 |
90 Days or More Past Due, Unpaid Principal Balance | 40,876 | 28,137 |
90 Days or More Past Due, Difference | $ (1,774) | $ (1,493) |
Fair Value of Financial Instr_7
Fair Value of Financial Instruments - Schedule of Net Gains (Losses) from Changes in Fair Value (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Fair Value Option Quantitative Disclosures [Line Items] | ||
Net (loss) gain on loans accounted for under the fair value option | $ (10,638) | $ 2,083 |
Loans held for sale | ||
Fair Value Option Quantitative Disclosures [Line Items] | ||
Net (loss) gain on loans accounted for under the fair value option | 120 | (351) |
Loans held for investment | ||
Fair Value Option Quantitative Disclosures [Line Items] | ||
Net (loss) gain on loans accounted for under the fair value option | $ (10,758) | $ 2,434 |
Fair Value of Financial Instr_8
Fair Value of Financial Instruments - Summary of the Activity Pertaining to Loans Accounted for Under Fair Value Option (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Loans held for sale | ||
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Balance at beginning of period | $ 16,198 | $ 17,745 |
Issuances | 3,045 | 13,635 |
Fair value changes | 120 | (351) |
Sales | (5,700) | |
Settlements | (212) | (36) |
Balance at end of period | 19,151 | 25,293 |
Loans held for investment | ||
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Balance at beginning of period | 824,520 | 885,527 |
Issuances | 61,611 | 30,108 |
Fair value changes | (10,758) | 2,434 |
Settlements | (43,947) | (49,415) |
Balance at end of period | $ 831,426 | $ 868,654 |
Fair Value of Financial Instr_9
Fair Value of Financial Instruments - Recorded Amount of Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis (Details) - Non-recurring Fair Value - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Collateral dependent loans | $ 2,349 | $ 1,245 |
Foreclosed assets | 6,744 | 5,612 |
Equity security investment with a non-readily determinable fair value | 8,738 | |
Total assets at fair value | 9,093 | 15,595 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Equity security investment with a non-readily determinable fair value | 8,738 | |
Total assets at fair value | 8,738 | |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Collateral dependent loans | 2,349 | 1,245 |
Foreclosed assets | 6,744 | 5,612 |
Total assets at fair value | $ 9,093 | $ 6,857 |
Fair Value of Financial Inst_10
Fair Value of Financial Instruments - Analysis of Level 3 Valuation Techniques (Details) $ in Thousands | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 1,461,120 | $ 1,418,904 |
Recurring | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | 884,904 | 876,745 |
Non-recurring Fair Value | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | 9,093 | 15,595 |
Non-recurring Fair Value | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | 9,093 | 6,857 |
Municipal bonds | Recurring | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 93 | $ 92 |
Municipal bonds | Discounted Expected Cash Flows | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Municipal bond, measurement input | 0.042 | 0.046 |
Municipal bonds | Discounted Expected Cash Flows | Prepayment speed | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Municipal bond, measurement input | 0.050 | 0.050 |
Loans held for sale | Recurring | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 19,151 | $ 16,198 |
Loans held for sale | Minimum | Discounted Expected Cash Flows | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.071 | 0.077 |
Loans held for sale | Maximum | Discounted Expected Cash Flows | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.154 | 0.214 |
Loans held for sale | Weighted Average | Discounted Expected Cash Flows | Prepayment speed | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.179 | 0.131 |
Loans held for investment | Recurring | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 831,426 | $ 824,520 |
Loans held for investment | Minimum | Discounted Expected Cash Flows | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.071 | 0.077 |
Loans held for investment | Minimum | Discounted Expected Cash Flows | Loss rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0 | 0 |
Loans held for investment | Minimum | Discounted appraisals | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.10 | 0.100 |
Loans held for investment | Maximum | Discounted Expected Cash Flows | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.154 | 0.214 |
Loans held for investment | Maximum | Discounted Expected Cash Flows | Loss rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.825 | 0.109 |
Loans held for investment | Maximum | Discounted appraisals | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.50 | 0.700 |
Loans held for investment | Weighted Average | Discounted Expected Cash Flows | Loss rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.018 | 0.013 |
Loans held for investment | Weighted Average | Discounted appraisals | Prepayment speed | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.179 | 0.131 |
Equity Warrant Assets | Recurring | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 702 | $ 570 |
Equity Warrant Assets | Black-Scholes Option Pricing Model | Discount rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.200 | 0.200 |
Equity Warrant Assets | Black-Scholes Option Pricing Model | Risk-Free Interest Rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.007 | 0.0190 |
Equity Warrant Assets | Minimum | Black-Scholes Option Pricing Model | Expected Volatility Rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.247 | 0.210 |
Equity Warrant Assets | Minimum | Black-Scholes Option Pricing Model | Expected Term | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 7 years | 8 years |
Equity Warrant Assets | Maximum | Black-Scholes Option Pricing Model | Expected Volatility Rate | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.854 | 0.750 |
Equity Warrant Assets | Maximum | Black-Scholes Option Pricing Model | Expected Term | Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 10 years | 10 years |
Collateral dependent loans | Non-recurring Fair Value | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 2,349 | $ 1,245 |
Collateral dependent loans | Minimum | Discounted appraisals | Discount rate | Non-recurring Fair Value | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.100 | 0.100 |
Collateral dependent loans | Maximum | Discounted appraisals | Discount rate | Non-recurring Fair Value | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.550 | 0.570 |
Foreclosed assets | Non-recurring Fair Value | Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Asset, fair value | $ 6,744 | $ 5,612 |
Foreclosed assets | Minimum | Discounted appraisals | Discount rate | Non-recurring Fair Value | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.040 | 0.100 |
Foreclosed assets | Maximum | Discounted appraisals | Discount rate | Non-recurring Fair Value | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Measurement input | 0.145 | 0.370 |
Fair Value of Financial Inst_11
Fair Value of Financial Instruments - Carrying Amount and Estimated Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Financial assets | ||
Cash and due from banks | $ 256,824 | $ 126,752 |
Federal funds sold | 158,226 | 96,787 |
Certificates of deposit with other banks | 7,250 | 7,250 |
Loans held for sale | 19,151 | 16,198 |
Loans and leases, net of allowance for credit losses on loans and leases | 831,426 | 824,520 |
Carrying Amount | ||
Financial assets | ||
Cash and due from banks | 256,824 | 126,752 |
Federal funds sold | 158,226 | 96,787 |
Certificates of deposit with other banks | 7,250 | 7,250 |
Loans held for sale | 976,899 | 950,249 |
Loans and leases, net of allowance for credit losses on loans and leases | 1,950,159 | 1,774,532 |
Financial liabilities | ||
Deposits | 4,642,148 | 4,229,122 |
Borrowings | 50,012 | 14 |
Estimate of Fair Value Measurement | ||
Financial assets | ||
Cash and due from banks | 256,824 | 126,752 |
Federal funds sold | 158,226 | 96,787 |
Certificates of deposit with other banks | 7,755 | 7,568 |
Loans held for sale | 1,044,207 | 1,004,135 |
Loans and leases, net of allowance for credit losses on loans and leases | 2,053,965 | 1,822,569 |
Financial liabilities | ||
Deposits | 4,717,676 | 4,213,657 |
Borrowings | 50,301 | 14 |
Level 1 | Estimate of Fair Value Measurement | ||
Financial assets | ||
Cash and due from banks | 256,824 | 126,752 |
Federal funds sold | 158,226 | 96,787 |
Certificates of deposit with other banks | 7,755 | 7,568 |
Level 2 | Estimate of Fair Value Measurement | ||
Financial liabilities | ||
Deposits | 4,717,676 | 4,213,657 |
Level 3 | Estimate of Fair Value Measurement | ||
Financial assets | ||
Loans held for sale | 1,044,207 | 1,004,135 |
Loans and leases, net of allowance for credit losses on loans and leases | 2,053,965 | 1,822,569 |
Financial liabilities | ||
Borrowings | $ 50,301 | $ 14 |
Commitments and Contingencies -
Commitments and Contingencies - Summary of Commitments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value Off Balance Sheet Risks Disclosure Information [Line Items] | ||
Total unfunded off-balance-sheet credit risk | $ 1,761,259 | $ 1,859,981 |
Commitments to Extend Credit | ||
Fair Value Off Balance Sheet Risks Disclosure Information [Line Items] | ||
Total unfunded off-balance-sheet credit risk | 1,732,944 | 1,834,449 |
Standby Letters of Credit | ||
Fair Value Off Balance Sheet Risks Disclosure Information [Line Items] | ||
Total unfunded off-balance-sheet credit risk | 27,512 | $ 25,532 |
Operating Lease Commitments | ||
Fair Value Off Balance Sheet Risks Disclosure Information [Line Items] | ||
Total unfunded off-balance-sheet credit risk | $ 803 |
Commitments and Contingencies_2
Commitments and Contingencies - Additional Information (Details) $ in Millions | 3 Months Ended | |
Mar. 31, 2020USD ($)Customer | Dec. 31, 2019USD ($) | |
Concentration Risk [Line Items] | ||
Commitment letters expiration period (in days) | 90 days | |
Commitments for on-balance-sheet investments | $ 16.9 | $ 16.9 |
Maximum retained credit exposure | 7.5 | |
Future minimum lease payments under non-cancelable operating leases | $ 83.1 | |
Thirty Relationships | ||
Concentration Risk [Line Items] | ||
Number of relationships that have retained unguaranteed exposure | Customer | 30 | |
Retained credit exposure | $ 325.7 | |
Retained exposure, amount disbursed | 217.4 | |
Four Relationships | ||
Concentration Risk [Line Items] | ||
Future minimum lease payments under non-cancelable operating leases | $ 59.8 |
Stock Plans - Narrative (Detail
Stock Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | May 24, 2016 | Mar. 31, 2020 | May 15, 2018 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares, granted (in shares) | 0 | ||
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation costs, stock options | $ 3.7 | ||
Unrecognized compensation costs period recognized | 2 years 4 months 6 days | ||
Market Restricted Stock | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation costs period recognized | 2 years 11 months 8 days | ||
Number of days share price must be maintained | 20 days | ||
Units earned as a percent of units awarded | 100.00% | ||
Shares, granted | 0 | ||
Unrecognized compensation costs | $ 12.6 | ||
Market Restricted Stock | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share price threshold for performance criteria (in dollars per share) | $ 34 | ||
Market Restricted Stock | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share price threshold for performance criteria (in dollars per share) | $ 55 | ||
Restricted Stock Units (RSUs) | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation costs, stock options | $ 16.2 | ||
Unrecognized compensation costs period recognized | 4 years 3 months 18 days | ||
Shares, granted | 483,331 | ||
Shares, granted, weighted average grant date fair value | $ 17.98 | ||
2015 Omnibus Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of common voting shares authorized (in shares) | 7,000,000 | ||
Options or restricted shares of expiration period | 10 years | ||
Percentage of fair market value of common stock | 100.00% | ||
2015 Omnibus Plan | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 3 years | ||
2015 Omnibus Plan | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of common voting shares authorized (in shares) | 8,750,000 | ||
2015 Omnibus Plan | Restricted Stock | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 7 years | ||
Annual Long Term Incentive Stock Compensation | Restricted Stock Units (RSUs) | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares, granted | 447,273 |
Significant Equity Method Inv_3
Significant Equity Method Investments - Summary of Balance Sheet Information of Equity Method Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Equity Method Investments And Joint Ventures [Abstract] | ||
Current assets | $ 52,228 | $ 56,710 |
Noncurrent assets | 176,472 | 162,304 |
Total assets | 228,700 | 219,014 |
Current liabilities | 20,183 | 19,910 |
Noncurrent liabilities | 664 | 683 |
Total liabilities | 20,847 | 20,593 |
Equity interests | 207,853 | 198,421 |
Total liabilities and equity | $ 228,700 | $ 219,014 |
Significant Equity Method Inv_4
Significant Equity Method Investments - Summary of Income Statement Information of Equity Method Investments (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Equity Method Investments And Joint Ventures [Abstract] | ||
Total revenues | $ 15,792 | $ 13,389 |
Net loss | $ (16,433) | $ (7,120) |